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ABSTRACT 
Patient-Derived Induced Pluripotent Stem Cells for Modeling Splicing Factor 
Retinitis Pigmentosa in Retinal Pigmented Epithelial Cells and Retinal 
Organoids 
by  
Leah P. Foltz 
Retinitis pigmentosa is the leading cause of inherited blindness, affecting 1 in 
3,000 individuals throughout the world. Advancements in genetic screening have 
helped the field identify the vast range of genetic mutations that can result in the 
retinal dystrophy observed in retinitis pigmentosa patients, but the underlying 
pathogenic mechanisms of these mutations are not well understood. Two major 
questions remain in understanding the pathology of this disease. First, the degree to 
which certain cell types are affected remains undetermined, namely the 
photoreceptors and their supportive retinal pigment epithelial cells. Second, the 
molecular mechanisms by which these diseases take place are not fully elucidated. In 
addition to being costly, animal models have limitations in recapitulating the 
pathology of these ocular diseases, especially with regards to patient-specific retinitis 
pigmentosa mutations. Induced pluripotent stem cells hold significant potential to 
elucidate the mechanisms of disease. This work characterizes the pathology of 
autosomal dominant retinitis pigmentosa and autosomal recessive retinitis 
pigmentosa using in vitro disease models with human cells. A point mutation in 
PRPF8, a ubiquitously expressed splicing factor, causes autosomal dominant retinitis 
 xi 
pigmentosa. This dissertation presents a novel cellular model of splicing factor 
retinitis pigmentosa using patient-derived, gene-corrected induced pluripotent stem 
cells. By differentiating both diseased and corrected cells into retinal pigmented 
epithelial cells and retinal organoids, genetic and functional analyses were performed 
to identify the differences between diseased and healthy retinal cells. Previously 
identified defects in murine retinal pigmented epithelial cell function were not 
identified in human retinal pigmented epithelial cells. By using unbiased RNA 
sequencing analysis, differences have been identified in the retinal pigmented 
epithelial cells at the level of long noncoding RNA and cell cycle regulation. Taken 
together, these finding highlight the importance of using human cells for disease 
modeling of the retina and the role of long noncoding RNA and cell cycle regulation 
in the pathology of splicing factor retinitis pigmentosa.  
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I. Patient-Derived Induced Pluripotent Stem Cells for Modeling Inherited 
Retinal Dystrophies  
 
 
ABSTRACT  
 
The human retina is a highly complex tissue that makes up an integral part of our 
central nervous system. It is astonishing that our retina works seamlessly to provide 
one of our most critical senses, and it is equally devastating when a disease destroys 
a portion of the retina and robs people of their vision. After decades of research, 
scientists are beginning to understand retinal cells in a way that can benefit the 
millions of individuals suffering from inherited blindness. This understanding has 
come about in part with the ability to culture human embryonic stem cells and the 
discovery of induced pluripotent stem cells, which can be cultured from patients and 
used to model their disease. In this chapter, we highlight the successes of specific 
disease modeling studies and resulting molecular discoveries. The greatest strides in 
cellular modeling have come from mutations in genes with established and well-
understood cellular functions in the context of the retina. We believe that the future 
of cellular modeling depends on emphasizing reproducible production of retinal cell 
types, demonstrating functional rescue using site-specific programmable nucleases, 
and shifting towards unbiased screening using next generation sequencing.* 
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A. Genetic Heterogeneity of Retinitis Pigmentosa 
 
The human retina consists of not just a few types of neurons, but rather is made 
up of around 55 different cell types1. Masland et al. 2001 describes the added 
complexities of the primate retina, which unlike some simpler mammals, consists of 
two types of horizontal cells, twenty-nine types of amacrine cells, between ten and 
fifteen different retinal ganglion cells, and so on.  In the context of disease modeling, 
it is hard to imagine that it is possible to recapitulate the highly complex, fundamental 
plan of the retina. The success of existing disease models suggests it is not necessary 
to produce all of these cell types in a way that mimics the positions and proportions 
they are found in vivo. Instead, the research produced thus far has elucidated 
molecular pathology by focusing on two of the most commonly affected cell types: 
photoreceptors and retinal pigmented epithelial cells (RPE).  
Inherited retinal dystrophies such as retinitis pigmentosa and Leber congenital 
amaurosis, cause degeneration of the retina and result in a loss of vision2. The 
pathology of these diseases has been documented in patients and animal models, 
which provide a limited amount of information about the cellular mechanisms of 
disease3,4. The retina makes up the posterior portion of the eye and consists of an inner 
and outer layer of neurons. The inner layer, consisting of ganglion, amacrine, bipolar, 
and horizontal cells, is generally less affected by retinal dystrophies than the outer 
layer, consisting of light-sensing photoreceptor cells and supportive retinal 
pigmented epithelial cells5.  
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Retinitis pigmentosa is the most commonly inherited retinal dystrophy, 
affecting approximately 1 in 3,000 individuals2. This disease is inherited in both 
autosomal dominant, autosomal recessive, and X-linked patterns and can be caused 
by a mutation in any one of more than 60 genes6,7.  
The disease begins with a loss of night vision, followed by peripheral vision, 
and in some cases results in complete blindness. While hyperpigmentation of the 
retina is a hallmark of the disease, the cellular and molecular mechanisms underlying 
this phenotype remain unclear. The most accepted hypothesis is that retinitis 
pigmentosa is a rod-cone dystrophy, with degeneration of rods preceding cones and 
later atrophy of retinal pigmented epithelial cells. There are some studies that suggest 
the retinal pigmented epithelial cells are predominantly affected in splicing factor 
mutations, such as pre-mRNA processing factors: PRPF3, PRPF8, and PRPF318. These 
data are based on a mouse model of the disease, and the results have yet to be 
replicated in a human cellular model.  
The first report of a disease model using patient-derived induced pluripotent 
stem cells (iPSCs) to study the pathology of retinitis pigmentosa in retinal cell types 
examined five patient cell lines spanning four known causative mutations: RP1, RP9, 
PRPH2, RHO9. The same researchers published a follow-up study in which they 
demonstrated rod degeneration in addition to the reported ER stress10. 
Several groups have been successful in modeling rhodopsin mutations in early 
disease models using two-dimensional photoreceptors. Jin et al. 2011 and 2012 
examined a G188R point mutation in RHO. A E181K point mutation in RHO resulted 
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in ER stress and was rescued in the two-dimensional photoreceptors using helper-
dependent adenoviral vector gene transfer11.  
One of the earliest studies using a three-dimensional multi-layer retinal 
organoid examined the pathogenicity of mutations in usherin (USH2A)12. While 
mutations in USH2A are commonly known to cause a syndromic Usher syndrome I, 
it is also known to cause non-syndromic retinitis pigmentosa13. The patient-derived 
photoreceptor precursors revealed ER stress, as was shown in the rhodopsin mutants.  
 In addition to identifying cellular stress caused by pathogenic mutations, stem 
cell disease modeling is also useful for identifying novel mutations. Early work with 
two-dimensional retinal progenitor cells demonstrated the pathogenicity of a novel 
Alu insert into male germ cell-associated kinase (MAK)14. More recent research 
identified novel variants in receptor expression-enhancing protein 6 (REEP6) in iPSC 
derived three-dimensional retinal organoids15. 
 Several disease models have examined pathology in RPE rather than 
photoreceptors. Membrane frizzled-related protein (MFRP) is an RPE-specific 
membrane receptor that resulted in actin disorganization in iPSC-derived RPE from 
two patients16. Researchers were able to rescue the actin organization and restore 
apical microvilli using an AAV8 vector containing MFRP.   
Later work introduced the use of translational read through inducing drugs 
(TRIDs) to show functional rescue in the case of premature stop codons. TRIDs were 
first used to rescue RPE with nonsense mutations in RP2 (ARL3 GTPase activating 
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protein)17. This work was expanded upon to show restoration of RP2 and rescue of 
cilia function in three-dimensional retinal organoids18. 
 Another case of RPE-specific disease modeling showed known causative 
mutations in MER receptor tyrosine kinase (MERTK) result in phagocytic defects in 
patient-derived RPE19. This work was expanded upon by again using TRIDs to restore 
the MERTK and functional rescue of phagocytosis20.  
 tRNA nucleotidyl transferase CCA-adding 1 (TRNT1) and X-linked retinitis 
pigmentosa GTPase regulator (RPGR) are the most recent additions to the growing 
list of iPSC disease models. In both studies, three-dimensional retinal organoids were 
produced from multiple patients using age or sex-matched controls, respectively. 
Various indels in TRNT1 resulted in autophagy defects and oxidative stress21. 
Deletions in RPGR resulted in abnormal actin polymerization and rhodopsin 
mislocalization and proposed a novel model for RPGR mediated actin regulation22.  
Future studies should focus on reproducing these findings in other patients 
with the mutations reported here and expanding to include other mutations that have 
yet to be modeled using iPSC. Any research that was conducted in two-dimensional 
retinal precursors should be repeated in three-dimensional retinal organoids, which 
more closely mimic the in vivo environment of photoreceptors.  
B. Patient-Derived Induced Pluripotent Stem Cells 
 
Induced pluripotent stem cells (iPSC) were initially produced from adult 
fibroblasts23,24. Fibroblasts are relatively accessible via a minimally invasive skin 
biopsy. There are now cases of iPSC production from other sources, including blood 
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and urine, which require even less invasive or entirely noninvasive procedures, 
respectively. Mononuclear blood cells or renal tubular cells are isolated from the 
blood or urine and used for reprogramming25,26. For example, activated T-cells were 
isolated from a routine peripheral blood sample to derive iPSCs and subsequently 
study a point mutation in visual homeobox 2 (VSX2)27. The same researchers had 
previously demonstrated that activated T-cell derived cells had the capacity to 
produce retinal cells and retinal organoids28. 
There is not currently a consensus on the preferred somatic cell source for 
producing iPSCs. In deciding upon which cell type is best going forward, the field 
considers the invasiveness of the procedure, the plasticity of the resulting stem cells, 
and the ability to differentiate into various retinal cell types. Research has shown that 
stem cells may retain cellular memory of the somatic cell source29. More research is 
needed to systematically determine the benefits and shortcomings of each potential 
cell source.  
Induced pluripotent stem cells, which were first described in 2007, are an essential 
tool in modeling inherited retinal dystrophies23,24. Reprograming methods have been 
reviewed thoroughly with regards to integrating versus non-integrating vectors25,30. 
The disease models described here use retroviral transduction, lentiviral transduction, 
non-integrating Sendai virus, or non-integrating episomal vectors (Table 3-7). More 
recent modifications have focused on adapting reprogramming methods to adhere to 
good manufacturing practices (GMP)31.   
C. Gene-Correction Using CRISPR/Cas9 
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Site-specific programmable nucleases include zinc-finger nucleases (ZFNs), 
transcription activator-like effector nucleases (TALENs), and most recently RNA-
guided engineered nucleases (RGENs), which have been thoroughly reviewed32. Kim 
and Kim et al. 2014 use the term RGENs to avoid confusion with the original CRISPR 
type II. Clustered regularly interspace short palindromic repeats (CRISPR)/CRISPR 
associated systems (Cas) were first described in the context of adaptive bacterial 
immunity33. All three of these nucleases are capable of creating double-stranded, site-
specific breaks in DNA, which triggers the endogenous DNA repair systems in 
eukaryotic cells. Although they share a similar mechanism of action, ZFNs, TALENs, 
and RGENs differ in terms of their success rate, mutation rate, target site length, off-
target effects, cytotoxicity, and size32.   
 The first several years of disease modeling for retinal dystrophies have relied 
on viral or drug mediated rescue of patient-derived cells. These techniques are 
limiting due to the packaging size limits of viruses or the need for a known drug 
target, respectively. For example, translation read-through inducing drugs have been 
useful for disease models of RP2, but this is only applicable to cases of premature stop 
codons17. The genetic heterogeneity of retinal dystrophies makes these diseases ideal 
candidates for precise gene editing by deciphering between subtle pathological 
differences caused by specific point mutations. Editing the genomic DNA allows the 
gene to remain under control of the endogenous regulatory elements, more accurately 
mimicking the disease state. 
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 Notably, Burnight et al. 2017 used CRISPR/Cas9 to generate gene-corrected iPSCs 
for multiple patient cell lines34. This work targeted three mutations in proteins 
previously studied in disease models: male germ cell-associated kinase (MAK), 
centrosomal protein 290kDa (CEP290), and rhodopsin (RHO). Early work with iPSCs 
and retinal progenitors derived from two retinitis pigmentosa patients revealed a 
pathogenic Alu insert in MAK14. The IVS26 cryptic splice mutation in CEP290 has 
been studied in fibroblasts and three-dimensional retinal organoids, demonstrating 
functional rescue of cilia via lentiviral transduction or antisense oligonucleotides35–37. 
Early interest in ZFN allowed researchers to engineer the nuclease to repair a common 
Pro23His rhodopsin mutation known to cause retinitis pigmentosa38. These three 
mutants were selected to demonstrate the efficacy of CRISPR for exonic mutations 
(MAK), intronic mutations (CEP290), and dominant gain-of-function (RHO)34. 
 While most of the retinal disease models discussed in this chapter do not use 
CRISPR, there are many non-retinal disease models that have successfully used 
CRISPR39. Researchers have started to provide gene-corrected iPSC lines as a lab 
resource, which will accelerate the use of CRISPR in retinal disease modeling as well 
as improve reproducibility between studies40. To address the concerns of line to line 
variability with passage of stem cells, Howden et al. demonstrated the ability to 
reprogram and gene edit iPSC simultaneously41. 
Although CRISPR/Cas9 has received a lot of attention as revolutionary gene-
correction technique, there is mounting concern about off-target effects. In the least, 
the intended gene target should be sequenced to confirm the desired effects, either 
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disruption or correction. Whole-genome sequencing allows for detection of insertion 
or deletions elsewhere in the genome. For both CRISPR and TALEN nucleases, WGS 
has revealed a low incidence of off-target mutations in human stem cells42. 
Improvement of CRISPR techniques have allowed development of Cas9 
endonucleases that are efficient without creating insertions and deletions (indels)30. 
Of some concern is the discovery that in vivo gene-correction results in single 
nucleotide variants in addition to indels43. Moving forward, researchers should be 
aware of any off-target effects when using RNA-guided engineering nucleases. 
D. Differentiation Methods: RPE and Retinal Organoids 
 
Prior to the discovery of induced pluripotent stem cells (iPSC), researchers had 
been developing spontaneous and directed differentiation of retinal cell types from 
embryonic stem cells. The first report of the spontaneous appearance of RPE was  
described in 2004, three years prior to production of human iPSC23,24,44. Spontaneous 
differentiation methods include any protocol in which the cell type of interest arises 
without addition of exogenous growth factors or small molecules. These protocols 
have the advantage of being technically easier than their directed counterparts.  
Directed differentiation methods involve the addition of growth factors and 
small molecules to mimic the in vivo developmental process of the retina. Various 
methods for directing differentiation of RPE in both suspension and adherent cultures 
has been thoroughly reviewed from 2008 through 201445. In 2015, a novel small-
molecule approach was developed using an unbiased approach to screen for RPE-
differentiation promoting factors46. It has been demonstrated that both spontaneous 
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and directed differentiation methods give rise to functional RPE across several 
embryonic and induced pluripotent stem cell lines47. Most recently, RPE 
differentiation that recapitulates normal development without the need for manual 
dissection, embryoid bodies, or suspension culture was developed48. 
In addition to RPE methods, other protocols have been developed to produce 
portions of the neural retina, including photoreceptors. Production of neural retina 
has been approached in both two-dimensional49,50 and three-dimensional methods51–
54. Various methods for directing differentiation of neural retina  in both two-
dimensional and three-dimensional cultures for human and mouse stem cells has 
been thoroughly reviewed from 2006 through 201755. 
 Capowski et al. 2016 demonstrated the patterning of iPSC-derived optic 
vesicles closely mimics development of the vertebrate eye. In that study, iPSCs were 
produced from a patient with a mutation in VSX2 (R200Q), which is known to cause 
microphthalmia27. The optic vesicles from the mutated cells had proliferation defects 
and a disproportionate amount of RPE differentiation when compared to the 
unaffected sibling.  RNA sequencing experiments revealed a significant effect on the 
expression of WNT genes, identifying a role for VSX2 and highlighting the usefulness 
of next generation sequencing in identifying novel roles for transcription factors56. The 
ability to mimic in vivo development of retinal tissue has also been confirmed in 
mouse stem cell lines57. Functional characterization by live imaging of retinal 
organoids further demonstrates the recapitulation of human development58.   
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E. Next generation sequencing 
 
In the simplest terms, a disease model is a causal model that investigates a cell 
or tissue with a defect that results in disease symptoms. In the case of retinal 
dystrophies, a patient harbors a mutational defect that results in blindness. A medical 
doctor must first identify the physical defects of the retina, properly diagnose the 
disease, and identify the genetic mutation. The identification of the underlying 
mutation requires a skin biopsy or blood sample from the patient, which can be used 
for subsequent gene sequencing and/or isolation of fibroblasts or mononuclear blood 
cells for production of iPSCs. These stem cells can then be provided to research 
laboratories for further analysis. Ideally, it would be possible to differentiate the 
induced pluripotent stem cells into a retinal cell type and notice an obvious defect 
when compared to a control. For reasons that will be discussed, stem cell disease 
models are not always able to immediately capture the molecular pathology of the 
underlying pathogenic mutation. For example, the study of rhodopsin mutations for 
retinitis pigmentosa have been revisited and refined over several years9–11. Causative 
mutations in another protein, CEP290 provides yet another example of a disease 
model that has evolved35–37,59. The purpose of identifying these research “stories” is to 
highlight the noticeable diversity of cellular disease models and the need for rigorous 
evaluation of each model.  
When discussing and evaluating stem cell disease models, it is important to 
identify the controls used for comparison to a patient-derived cell line. There are three 
models that are frequently employed for investigating IRDs. These involve 
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comparison of patient-derived cells to 1) wild-type cells, 2) age-matched, sex-
matched, or sibling cells, or 3) genome-edited patient-derived cells. In earlier work, 
wild-type iPSC lines were generally accepted as controls, but with a deeper 
understanding of line-to-line variability, models are strengthened by the use of sibling 
controls, or age and sex matched controls in the very least60.  
We believe a criterion standard of cellular disease models would fulfill at least 
four basic criteria: (1) the model would include stem cell lines from multiple patients 
harboring the same mutation, (2) the model would compare the diseased patient cells 
to a gene-corrected version, (3) in addition to the gene-corrected cells, an additional 
age-matched, sex-matched wild-type control would be included, and (4) any 
functional rescue would be connected to the function of the mutated gene in some 
way (Figure 1). In practice, it is not always feasible to attain this level of control in 
every cellular model and a study shouldn’t necessarily be disregarded if it does not 
obtain one or more of the criteria. 
With regards to the first criterion, researchers may not have access to patient-
derived cell lines and instead introduce the mutation into a wild-type cell line. If this 
model recapitulates the disease phenotype, it can be said with a reasonable degree of 
certainty that the mutation is sufficient. Researchers may have access to a patient,  
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 (A) One or multiple (n) patients and one or multiple (n) wild-type individuals 
are identified for isolating somatic cells and producing iPSC. (B) Upon 
reprogramming, patient cells will harbor the mutation, as indicated in red, 
and wild-type cells will not, as indicated in green. (C) Site-specific 
programmable nucleases can be used to correct the patient mutation or 
introduce the patient mutation in the wild-type samples. (D) After 
differentiation, cells with and without the mutation can be genetically and 
functionally analyzed. (E) if the introduction of the mutation mimics the 
patient-derived cells, the mutation is sufficient to cause the observed disease 
phenotype. (F) If the correction of the mutation mimics the wild-type cells, the 
mutation is necessary to cause the observed disease phenotype.  
 
Figure 1. Overall workflow for designing and implementing an iPSC disease 
model.   
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but due to the heterogeneity of retinal dystrophies, it may not be feasible to locate 
multiple patients with the same mutation.   
Regarding the second criterion, precise gene editing requires a level of 
expertise that is not always available to researchers. Genome editing may introduce 
off target effects that confound results, again highlighting the approach of introducing 
a mutation into a wild-type cell line to prove sufficiency5. Overexpression of disease 
causing genes in non-retinal cell types has had some success, but this method does 
not recapitulate endogenous regulation61,62. 
The third criterion is relatively easy to satisfy now that numerous iPSC lines 
are commercially available based on age, sex, disease state, etc. With regards to the 
fourth criterion, there are a limited number of functional assays that have been 
established for retinal cell types. The underlying molecular pathology for a specific 
mutation may not be connected to a function that can be easily measured in vitro. For 
example, it is more convincing to demonstrate the role of CEP290 in ciliogenesis rather 
than demonstrating a general decrease in cell viability or increase in cellular stress35–
37,59. As the field of stem cell disease modeling progresses, it is critical to reassess our 
criteria for a convincing model and will need to be done on a case-by-case basis.  
F. Future Directions  
From the existing studies, it is reasonable to state that disease modeling 
inherently involves several layers of heterogeneity. The diseases themselves result 
from numerous different mutations across dozens of different genes. There are several 
sources of somatic cells for stem cell production by a variety of different 
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reprogramming methods. Each of those resulting stem cell populations can then 
undergo a plethora of differentiation protocols for producing retinal cell types. This 
inherent heterogeneity is important to consider because it may affect the 
reproducibility of disease models. As the field moves forward, it will be vitally 
important to provide thorough protocols to allow other researchers to repeat and 
build upon findings.  
Clinical trials using RPE are already underway for other degenerative diseases, 
such as age-related macular degeneration, and trials using photoreceptors or other 
retinal cell types are on the horizon. The field of disease modeling is critical to the 
success of these trials because functional findings will inform researchers as to which 
cell types are primarily affected.  
With the promise of cellular therapies, it is important to work towards using 
protocols that adhere to good manufacturing practice, which includes the 
development of xeno-free protocols for differentiation of retinal cell types31,63,64.*  
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G. Conclusions 
The following chapters demonstrate the application of iPSC disease modeling 
to splicing factor autosomal dominant retinitis pigmentosa (RP13) and autosomal 
recessive retinitis pigmentosa (RP12). Chapter II is a detailed protocol for the 
production of retinal pigmented epithelial cells for subsequent disease modeling and 
was originally published in the Journal of Visualized Experiments. Chapter III 
summarizes the findings in retinal pigmented epithelial cells differentiated according 
to the protocol in chapter II, using patient-derived, gene-corrected stem cells as a 
starting material. Finally, Chapter IV explores the use of retinal organoids for 
modeling two forms of retinitis pigmentosa: autosomal dominant RP13 as caused by 
a point mutation in pre-mRNA processing factor 8 (PRPF8) and autosomal recessive 
RP12 as caused by a point mutation in crumbs 1 (CRB1).  
 
 
 
 
 
 
*This chapter was published as Foltz, L. P. & Clegg, D. O, “Patient-derived induced 
pluripotent stem cells for modelling genetic retinal dystrophies,” Progress in Retinal 
and Eye Research, 2018.  
Copyright 2018 Progress in Retinal and Eye Research.  
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II. Rapid, Directed Differentiation of Retinal Pigment Epithelial Cells from 
Human Embryonic or Induced Pluripotent Stem Cells  
 
 
ABSTRACT 
This protocol describes how to produce retinal pigment epithelial cells (RPE) 
from pluripotent stem cells. The method uses a combination of growth factors and 
small molecules to direct the differentiation of stem cells into immature RPE in 
fourteen days and mature, functional RPE after three months. We describe a robust 
method to direct the differentiation of pluripotent stem cells into retinal pigment 
epithelial cells (RPE). The purpose of providing a detailed and thorough protocol is 
to clearly demonstrate each step and to make this readily available to researchers in 
the field. This protocol results in a homogenous layer of RPE with minimal or no 
manual dissection needed. The method presented here has been shown to be effective 
for induced pluripotent stem cells (iPSC) and human embryonic stem cells. 
Additionally, we describe methods for cryopreservation of intermediate cell banks 
that allow long-term storage.  RPE generated using this protocol might be useful for 
iPSC disease-in-a-dish modeling or clinical application.* 
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A. Introduction   
The retinal pigment epithelium is a monolayer of pigmented cells that provide 
crucial support for photoreceptors. Retinal pigment epithelial cells (RPE) have 
numerous functions in vision, including light absorption, nutrient and ion transport, 
the retinoid cycle, phagocytosis of photoreceptor outer segments, and growth factor 
secretion65. There are a variety of retinal dystrophies that affect the function of RPE 
and result in a loss of vision, including age-related macular degeneration and retinitis 
pigmentosa. Generation of RPE from pluripotent stem cells may facilitate research to 
understand these eye diseases, and can provide an unlimited source of RPE for cell 
therapies45. In fact, multiple clinical trials are underway using RPE derived from 
pluripotent stem cells66.  
This differentiation protocol was originally described by Buchholz et al. 2014 
and was based on the previously published method from Clegg67,68. The procedure 
mimics the normal in vivo developmental process to direct undifferentiated 
pluripotent stem cells towards an RPE fate via manipulation of the IGF, FGF-2 (FGF-
basic), TGF-beta, and WNT pathways67,68. The protocol was significantly improved by 
addition of a WNT pathway agonist late in the protocol, which yielded 97.77% ± 0.1% 
PMEL (pre melanosome protein) positive cells, and has been adapted to xeno-free 
conditions69,70.  The resulting RPE have been shown to express RPE markers at the 
transcript and protein levels, to secrete known RPE growth factors with appropriate 
polarity, and carry out phagocytosis of photoreceptor outer segments47.  This 
protocol is more rapid and reliable than “spontaneous” protocols of differentiation 
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that involve simple removal of basic fibroblast growth factor47. Furthermore, RNA 
sequencing data show that RPE obtained using this protocol are very similar to those 
obtained using the more common spontaneous approach47. The 14-day method 
generates RPE that fit the “5 P’s” mentioned by Mazzoni et al. 2014 (pigmented, 
polarized, phagocytic, post-mitotic, polygonal)71. Several additional directed 
differentiation methods have been published in recent years46,48,72,73.  
 
B. Materials and Methods 
1. Preparation of reagents for day 0 to day 14 of the protocol.   
1.1. Prepare the following medium components:   
1.1.1.  Make 100 mL of Retinal differentiation medium (RDM) by adding 1 mL of 
100X N2 supplement, 2 mL of 50X B27 supplement, and 1 mL of 100X NEAA (non-
essential amino acids) to 96 mL of DMEM/F12 (Dulbecco’s modified essential 
medium, nutrient mixture F12). 
1.1.2.  Make 10 mL of 1 M Nicotinamide (NIC) by dissolving 1.221 g of NIC in 8 mL 
of sterile water, vortexing, and bringing the volume to 10 mL with sterile water. Sterile 
filter the solution.  
1.2.  Prepare the following growth factors and small molecules: 
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1.2.1.  Reconstitute recombinant mouse noggin, human DKK-1 (dickkopf WNT 
signaling pathway inhibitor 1), and IGF-1 (insulin-like growth factor 1) to 100 µg/mL 
in 0.1% BSA in PBS.  Aliquot as needed and store at -20 °C for up to 3 months. 
1.2.2.  Reconstitute FGF-basic (fibroblastic growth factor-2) to 10 µg/mL and 
recombinant human/mouse/rat Activin A to 100 µg/mL in 0.1% BSA in PBS. Aliquot 
as needed and store at -80 °C for up to 1 year.  
1.2.3.  Reconstitute SU 5402 (FGFR-specific tyrosine kinase inhibitor) and CHIR99021 
(GSK-3b inhibitor) in DMSO to 10 mM each. Aliquot and store at -20 °C for up to 1 
year or 6 months, respectively.  
1.3.  Obtain the following for day 0 and/or day 14: 1X EDTA solution (0.2 g 
ethylenediaminetetraacetic acid per liter of PBS), 1X PBS -/- (phosphate-buffered 
saline without calcium or magnesium, pH 7.4), 1X trypsin-like dissociation enzyme 
(TDE), DPBS (Dulbecco’s phosphate-buffered saline), any RPE supporting medium 
(RSM), and Y-27632 dihydrochloride (use at 10 µM).  
2.  Day 0: Day of pluripotent stem cell passage for differentiation.  
2.1.  Grow stem cell colonies in feeder-free, serum-free conditions to approximately 
80% confluence before passaging.  
Note: See discussion for details on optimizing this step. 
2.2.  Coat a 12-well plate with non-growth factor reduced natural extracellular 
matrix-based hydrogel (ECM) as per manufacturer recommendations. Allow to set for 
1 h at room temperature or overnight at 4 °C.   
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2.3.  Aliquot the volume of RDM and PBS -/- needed for day 0 and warm in a water 
bath to 37 °C before adding growth factors. Bring EDTA to room temperature. 
2.4.  Add the growth factors necessary for day 0 to the warmed RDM with 10 mM 
NIC, 50 ng/mL noggin, 10 ng/mL DKK-1, 10 ng/mL IGF-1. From the stocks described 
in step 1.2, add 100 µL of NIC, 5 µl of noggin, 1 µL of DKK-1, and 1 µL of IGF-1 to 10 
mL of RDM.  
2.5.  Pick to remove all differentiated colonies based on morphology from the stem 
cells that will be passaged for differentiation. Use a P10 pipet tip to manually remove 
the differentiated cells.  
Note: Fibroblastic cells between colonies as well as the opaque cells within colonies 
indicate differentiated cells to be removed. See discussion for details about 
differentiated cells.  
2.6.  Passage a single well of a 6-well plate into 4 wells of a 12-well plate (1:4).  
Note: See discussion for details on passaging stem cells at this stage. 
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2.6.1. Aspirate the stem cell medium from the stem cells and wash the wells once 
with pre-warmed PBS -/-.  
2.6.2.  Aspirate PBS -/- and rinse each well three times with 1 mL of EDTA per well 
of a 6-well plate.  
2.6.3.  Gently tilt the plate and aspirate the EDTA. Do not agitate the plate in any way 
to avoid prematurely lifting the cells.  
2.6.4.  After the third wash, add 1 mL of EDTA and incubate at room temperature in 
the hood for 3-5 min. Do not disturb the plate during this incubation.  
2.6.5.  Aspirate the EDTA and add 1 mL of RDM per well that will be seeded with 
0.5 mL of extra medium. For example, wash 1 well of a 6-well plate with 4.5 mL of 
RDM to plate on 4 wells of a 12-well plate.  
2.6.6.  Use a cell scraper to gently detach the cells. Collect all cells in a conical tube 
and triturate the cells in RDM by pipetting up and down 5 times. Dissociate large 
clumps of cells but do not triturate to single cell suspension. Distribute the cells evenly 
in the pipet. Complete this step quickly to prevent reattachment to the plate.  
2.6.7.  Seed cells on the ECM-coated 12-well plates (1 mL of cell suspension per well).  
2.6.8.  Tilt the plate back and forth and gently place in a cell culture incubator at 37 
°C and 5% CO2 to remain in culture until the next medium change. Distribute the cells 
evenly throughout the wells. 
2.6.9.  Note the exact time. Change medium at the same time each day. 
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3.  Day 1 to 14 of the 14-day differentiation protocol. 
3.1.  Day 1: Change the medium on all wells (1 mL per well) using RDM with the 
growth factor composition for day 0.  
3.2.  Day 2: Change the medium using RDM (1 mL per well) with 10 mM NIC, 5 
ng/mL FGF-basic, 10 ng/mL noggin, 10 ng/mL DKK-1, 10 ng/mL IGF-1. From the 
stocks described in step 1.2, add 100 µL of NIC, 5 µL of FGF-basic, 1 µL of noggin, 1 
µL of DKK1, and 1 µL of IGF1 to 10 mL of RDM.  
3.3.  Day 4: Change the medium using RDM (1 mL per well) with 100 ng/mL 
activin A, 10 ng/mL DKK-1, 10 ng/mL IGF-1. From the stocks described in step 1.2, 
add 10 µL of activin A, 1 µL of DKK1, and 1 µL of IGF-1 to 10 mL of RDM.  
Note: Observe that cells are confluent at this stage.  
3.4.  Day 6: Change the medium using RDM (1 mL per well) with 100 ng/mL 
activin A, 10 µM SU 5402. From the stocks described in step 1.2, add 10 µL of activin 
A and 10 µL of SU 5402 to 10 mL of RDM. 
3.5.  Days 8, 10, and 12: Change the medium using RDM (1 mL per well) with 100 
ng/mL activin A, 10 µM SU 5402, 3 µM CHIR99021. From the stocks described in step 
1.2, add 10 µL of activin A, 10 µL of SU 5402, and 3 µL of CHIR99021 to 10 mL of RDM.  
4.  Day 14: Day of enrichment to passage 0 RPE. 
4.1.  Coat a 6-well plate with growth factor reduced ECM as per manufacturer 
recommendations. Allow to set for 1 h at room temperature or overnight at 4 °C.  
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4.2.  Aliquot the volume of DPBS needed and 1 mL of RDM per well of enrichment 
and warm in a water bath to 37 °C. Bring the TDE to room temperature and warm 
necessary volume of RSM (+0.5X antimicrobial reagent, +/- Y-27632) to 37 °C.  
4.3.  Add Y-27632 to RSM to obtain a 10 µM composition. Use this medium for the 
first 4-7 days to improve attachment.  
4.4.  Aspirate spent medium from all wells and add 1 mL per well of pre-warmed 
RDM (no growth factors required).  
4.5.  Using a dissecting microscope, manually dissect and scrape away all non-RPE 
cells using a P10 pipet tip.  
Note: See the representative results section for examples. 
4.6.  After dissection, aspirate RDM and all cell debris. Wash twice with 1 mL of 
pre-warmed DPBS per well.  
4.7.  Add 0.5 mL of TDE per well of a 12-well plate and incubate at 37 °C for 5 min. 
Use a cell scraper to gently remove the cells from the plate. Use a P1000 pipet to gently 
triturate the cell/TDE suspension 3-4 times to create a uniform suspension. 
4.8.  Dilute the cell/TDE suspension 1:10 in pre-warmed RSM, without Y-27632. 
Centrifuge cell suspension at 173 x g for 5 min at room temperature.  
4.9.  Aspirate the medium from the cell pellet and resuspend the cells in RSM with 
10 µM Y-27632 (1 mL per enriched well).  
4.10.  Strain the cells using a nylon mesh cell strainer with 40 µm pores. Count the 
number of cells in a specified volume using a hemocytometer and calculate the 
concentration of cells in the strained solution.  
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4.11.  Seed cells on the growth factor reduced ECM-coated plates at 1x105 cells/cm2.  
4.12.  Change the RSM with 10 µM Y-27632 48 h after cell seeding. Remove the 10 
µM Y-27632 between days 4-7.  
4.13.  Allow the cells to mature for 28 to 35 days at 37 °C and 5% CO2. Continue to 
change the RSM every 3-4 days (e.g. on Mondays and Thursdays). 
5.  Maturing the RPE: Passage 0 to passage 1/passage 1 to passage 2;  
Note: volumes are indicated for 1 well of a 6-well plate or a T75 flask as indicated by 
parentheses. 
5.1.  Between days 28 to 35 of passage 0, coat a 6-well plate (or T75 flask) with non-
growth factor reduced ECM as per manufacturer recommendations.  
5.2.  Aliquot the volume of DPBS and RSM needed and warm in a water bath to 37 
°C. Bring TDE to room temperature. 
5.3.  Aspirate spent medium from wells and wash each well twice with 2 mL (10 
mL) of pre-warmed DPBS.  
5.4.  Aspirate DPBS and add 1mL (5mL) of TDE. Place in incubator at 37 °C and 5% 
CO2 for 5 min. After incubation, view cells on an inverted microscope to confirm the 
cells are contracting and detaching.  
5.5.  Using an appropriately sized cell scraper, gently remove the cells from the 
bottom of the well or flask.  
5.6.  Use a P1000 tip (10mL serological pipet) to gently triturate the cell/TDE 
suspension 3-4 times to create a uniform suspension.  
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5.7.  Dilute cell suspension 1:10 in RSM. Reserve 2mL (5mL) of RSM to rinse the 
well/flask and add to the diluted cell suspension. Do not allow enzyme exposure 
time to exceed 25 min.  
5.8.  Centrifuge the cell suspension at 173 x g for 5 min at room temperature.  
5.9.  Aspirate the medium from the cell pellet and resuspend the cells in RSM  
Note: Only use 10 µM Y-27632 at passage 0, not at passage 1 and beyond.  
5.10.  Strain the cells using a nylon mesh cell strainer with 40 µm pores. Count the 
number of cells in a specified volume using a hemocytometer and calculate the 
concentration of cells in the strained solution.  
5.11.  Seed cells on the ECM-coated plates at 1x105 cells/cm2.  
5.12.  Allow the cells to mature for 30 days. Continue to change the RSM every 3-4 
days. 
5.13.  Repeat the above procedure at day 30 to passage the cells from passage 1 to 2.  
6.  Creating an intermediate cell bank: Cryopreservation of passage 2 day 3-5 
RPE.  
Note: Cryopreserve cells while they are subconfluent (~50%) and have not regained 
pigment.  
6.1.  Based on the number of cells, calculate the volume of animal component-free, 
defined cryopreservation medium with 10% DMSO (dimethyl sulfoxide) needed to 
resuspend the cells at a concentration of 3x106 cells/mL.  
6.2.  Follow steps 5.2 to 5.8. Resuspend the cell pellet in the cryopreservation 
medium and transfer 1mL of the cell suspension to 1.2 mL cryogenic vials.  
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6.3.  Place cryogenic vials in a freezing container designed to cool at -1 oC/min and 
place at -80 °C overnight. Transfer to liquid nitrogen for long-term storage.  
Note: These cells will be passage 3 upon thawing. Culture the cells for 30 more days 
before characterization. Seed passage 3 RPE at 1.5x105 per cm2 upon thawing.  
 
C. Results 
This method results in the production of a homogeneous, pigmented, and 
cuboidal monolayer of RPE. The timeline in Figure 2 corresponds to the images 
depicted in A-F. As shown in Figure 2A, the stem cell colonies are tightly packed with 
defined edges and no fibroblastic cells between colonies or opaque cells within 
colonies.  
Figure 2B provides a representation of immature RPE that are subconfluent. If 
the cells are already confluent at this stage, they cannot extend projections that are 
critical to the differentiation process. However, if cells are severely subconfluent, they 
will not be able to begin forming tight junctions characteristic of epithelial cells. 
Details on how to optimize this confluence are outlined in the discussion section.  
Figure 2C shows the morphology of the two most common types of non-RPE that may 
come about during this differentiation process: neural ribbons and defined patches. It 
is important to note that these neural ribbons appear especially opaque on a dissecting 
microscope whereas the defined, fibroblastic-like patches are nearly translucent on a 
dissecting microscope. It can be helpful to mark these areas on a tissue culture plate 
with an ethanol-proof lab pen to more easily identify them on both a compound 
microscope and dissecting microscope.  
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Figures 2D-F show the characteristic bright borders, cobblestone morphology, and 
pigmentation that indicate a healthy, maturing culture of RPE.  
Figure 3 is a higher magnification image to show the different appearance of fully 
mature RPE depicted by phase contrast and bright field microscopy. At passage 3 day 
30, the cells are ready for the characterization that has been described in previous 
publications, including RNA expression, protein expression, growth factor secretion, 
and phagocytosis45,67,69,70. These characterizations show that the cells represented in 
these images are not only pigmented and cuboidal, but also phagocytic, post-mitotic, 
and polarized.  
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Growth factors are added to 12-well plates from day 0-14. Maturing RPE are 
cultured in 6-well plates or T75 flasks from day of enrichment to 30 days post-
thaw (passage 3 day 30). Arrows indicate enzymatic cell passaging. A-E below 
the timelines correspond to the images. Induced pluripotent stem cells 
immediately before passaging for differentiation (A). Immature RPE cells 
subconfluent at day 2 (B) and before pick-to-remove enrichment on day 14; 
non-RPE patches (indicated by white arrows) appear as patches or opaque 
"ribbons" (C). RPE at passage 0, 1, and 3 on day 30 (D, E, and F). Scale bar 
equals 200 µm.  
Figure 2. Timeline for the addition of growth factors and maturation of RPE 
Representative morphology and confluence of maturing RPE. 
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Cuboidal morphology depicted in phase contrast (A) and pigmentation 
depicted in bright field (B). Scale bar equals 50 µm. 
 
Figure 3. Mature RPE at passage 3 day 30 
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D. Discussion  
This protocol describes how to produce retinal pigment epithelial cells from 
pluripotent stem cells. The method was optimized using both human embryonic and 
iPSC from a feeder-free, serum-free culture method. Since the initial isolation of 
human embryonic stem cells in 1998 and the derivation of induced pluripotent stem 
cells (iPSC) in 2007, scientists have developed a multitude of stem cell culture 
methods23,24,74,75. These methods should be sufficient for producing stem cell colonies 
that are susceptible to this differentiation. There are no known limitations to the 
applicability of this method to properly derived and maintained pluripotent stem 
cells.  
The most critical steps are the passaging of stem cells to day 0 of differentiation 
(step 2.4-2.5) and the potential need for manual dissection at day 14 of the process 
(step 4.5). When picking to remove differentiated cells from the stem cell colonies 
(step 2.4), it is helpful to refer to the images in Kent et. al. 2009. As indicated, the 
fibroblastic cells between colonies as well as the opaque cells within colonies indicate 
differentiated cells and need to be removed before beginning this protocol76. Only 
undifferentiated, tightly packed colonies with defined edges should be passaged for 
differentiation.  
The number of stem cells seeded per well is complicated by the fact that the 
stem cells cannot be triturated into a single cell suspension upon passage and cannot 
be accurately counted using a hemocytometer. The approximation of 80% confluent 
stem cells is indicated for passaging 1 well of a 6 well plate into 4 wells of a 12-well 
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plate. Differences between stem cell lines, such as growth rate, can affect how quickly 
the immature RPE reach confluence between days 0 to 4. The stem cells will produce 
RPE regardless of precise confluence; however, the cell yield will be negatively 
affected if the cells are too sparse early in the protocol. The immature RPE cells should 
be approximately 40-50% confluent on day 1 and nearly 100% confluent by day 4. If 
the cells are not producing a confluent monolayer by day 4 or 6, the protocol should 
be repeated at a higher seeding density at day 0. For example, if one well of a 6-well 
plate was passaged to 4 wells of a 12-well plate at day 0 and the immature RPE are 
not 100% confluent at day 4, reduce the seeding to a 1:3 or 1:2 passage on day 0 or 
allow the stem cells to become more confluent before passaging. It is critical to 
establish a consistent seeding density when comparing multiple cell lines.   
The manual dissection step at day 14 is only necessary when non-RPE are 
present in culture (Figure 2C). Since the addition of CHIR99021 to the protocol, many 
pluripotent stem cell lines require little to no manual dissection. Some preparations 
have a higher incidence of neural patches and it is critical to remove those cells. If the 
RPE are not viable at passage 0 and beyond, it is possible to repeat the differentiation 
protocol taking sufficient time to remove all non-RPE cells. This does not happen 
often, but it is mentioned here to note that the dissection step on day 14 can be 
optimized when needed. 
There are a variety of RPE differentiation protocols that vary in cost as well as 
culture methods, efficiency, quantification, and functional assessment, the latter of 
which has been reviewed thoroughly45. We prefer the 14-day method detailed here 
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because of its efficacy, adaptability, and applicability to a wide range of cell lines47,67,70.  
The cryopreservation step in this protocol also provides a major advantage in creating 
an intermediate cell bank for future use, avoiding lot-to-lot variability in experiments. 
Starting with only 4 wells of a 12-well plate, it is possible to expand into 6 well plates 
at passage 0 and T75 flasks at passage 1 and 2. At passage 2 day 3-5, when the cells 
are still subconfluent and have not regained pigment, it is possible to cryopreserve 
tens of millions of cells and then thaw the mature RPE, designated passage 3 day 30, 
to check RNA expression, protein expression, growth factor secretion, phagocytosis, 
etc. We have also established protocols to expand RPE for up to 13 passages77.  
Looking forward, this method will be useful for iPSC modeling of ocular disease and 
for generation of RPE for cellular therapy. With regards to iPSC disease modeling, 
this protocol is currently being used in the lab to produce RPE from CRISPR-corrected 
lines with non-corrected controls from the same patient. Furthermore, this protocol is 
adaptable to synthetic substrates and xeno-free conditions that are useful for adhering 
to the good manufacturing practices required for a cellular therapy.* 
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E. Conclusions 
The protocol described in this chapter was used to produce a homogeneous 
population of RPE from multiple patient-derived gene-corrected iPSC lines for 
subsequent disease modeling. The purpose of providing a detailed protocol is to 
highlight the importance of a robust differentiation method. The cells produced by 
this method are shown to be similar in their morphology, gene expression, protein 
localization, and functional ability. The striking similarity of the cells produced by 
this method allows for a robust disease model that can identify and explore minute 
differences between cells as described in chapter III. By publishing this method in 
great detail, we have enabled other scientists to apply this technique to their own 
disease models, which will further our collective knowledge surrounding the effect of 
retinal dystrophies on retinal pigmented epithelial cells.   
 
 
 
 
 
 
*This chapter was published as Foltz, L. P. & Clegg, D. O. Rapid, Directed 
Differentiation of Retinal Pigment Epithelial Cells from Human Embryonic or 
Induced Pluripotent Stem Cells. J. Vis. Exp. 9, 2–7 (2017). 
Copyright 2018 Journal of Visualized Experiments.  
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III. Transcriptome Analysis and Functional Assessment of Patient-Derived 
Retinal Cells Edited by CRISPR/Cas9 
 
ABSTRACT 
 We demonstrate that retinal pigmented epithelial cells (RPE) produced from 
patient-derived induced pluripotent stem cells (iPSC) are morphologically and 
functionally similar to wild-type RPE in vitro. RPE produced by directed 
differentiation methods from three diseased and three gene-corrected induced 
pluripotent stem cell lines were analyzed in terms of gene and protein expression, 
apicobasal polarity, and phagocytic ability. Functionally, the diseased and gene-
corrected RPE were able to establish apicobasal polarity and phagocytose 
photoreceptor outer segments at the same capacity as wild-type RPE. These data 
suggest that patient derived diseased and gene-corrected iPSC are able to differentiate 
into RPE, thus allowing for the establishment of a well-controlled disease model. In 
this study, we performed RNA-sequencing for patient-derived retinal pigmented 
epithelial cells and retinal organoids to identify differentially expressed genes. The 
RPE that were studied were purified populations of cells, which allows for reduction 
of background based on cell-to-cell variability. We identified differentially expressed 
genes in RPE and demonstrated the up-regulation of a lncRNA and REC8 in the 
diseased RPE, implicating the role of lncRNA and cell cycle regulation in 
pathogenesis. These data showed that there is minimal line-to-line variability from a 
single patient, allowing for identification of differentially expressed genes that relate 
to a genetic mutation.  
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A. Introduction  
Retinitis pigmentosa is the most common form of inherited blindness and can 
be caused by a multitude of different genetic mutations that lead to the same 
phenotype. Specifically, mutations in ubiquitously expressed splicing factor proteins 
are known to cause an autosomal dominant form of the disease, but the retina specific 
pathology of these mutations is not well understood. In this study, we examined the 
cellular pathology of splicing factor autosomal dominant retinitis pigmentosa (RP13). 
Mutations in ubiquitously expressed proteins provide a unique challenge for 
understanding pathology. In the case of RP13, it is known that the retina is the 
specifically affected tissue, but the cellular specificity has not been determined. The 
two most commonly affected retinal cells are photoreceptors and their supportive 
retinal pigmented epithelial cells (RPE). To investigate the effect of a patient-specific 
point mutation in a specific retinal cell type, it is critical to produce a homogenous cell 
population. In this study, we have produced a purified population of RPE to 
investigate the molecular pathology.  
Mutations in three pre-mRNA processing factors are known to cause 
autosomal dominant retinitis pigmentosa: PRPF3, PRPF8, and PRPF31. Early 
investigation of 150 Spanish families positively identified specific point mutations in 
PRPF3, PRPF31, and PRPF892. RP13 is used to refer to the form of the disease caused 
by one of several known causative mutations in PRPF8. The mechanism by which a 
mutation that affects alternative splicing causes retinitis pigmentosa is unknown6,90,91.   
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The human pre-mRNA processing factor 8 (PRPF8) gene encodes a protein that 
is ubiquitously expressed and is one of the largest and most highly conserved nuclear 
proteins80. PRPF8 was first identified as the 220kDa mammalian homolog of the yeast 
PRP8 protein, a component of the U5 small nuclear ribonucleotide complex in the 
spliceosome65–67. The role of PRPF8 in pre-messenger (pre-mRNA) splicing has been 
a topic of investigation for nearly twenty years and has been investigated by a variety 
of methods to help elucidate the function of this protein in the context of RNA 
splicing84–86. Pre-mRNA splicing is critical for the proper removal of introns to allow 
for subsequent protein translation87. Crystallographic studies in yeast have shown 
that mutations in PRFP8 disrupt protein-protein interactions, but these results have 
not been confirmed in human protein models88,89. 
RPE are highly polarized cells and their function depends heavily on their 
apical basal polarity. In a functioning retina, the apical microvilli bind and 
internalize the photoreceptor outer segments. It is possible to assess this function in 
vitro and will prove to be relevant to modeling RP13. Animal models have shown that 
the RPE cells of splicing factor knockout mice are unable to phagocytose rod-outer 
segments efficiently8. Specifically, RPE from PRPF8 knockout mice were subjected to 
a rod-outer segment phagocytosis assay, and the researchers found a 37-48% decrease 
in phagocytosis. Using established imaging techniques, it was shown that the cells 
were deficient in binding of the outer-segments rather than internalization78. Further 
examination by immunofluorescence showed that the localization of some adhesion 
and phagocytosis proteins was perturbed in the PRPF8 knockout mice. For example, 
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although the αV integrin was correctly expressed on the apical membrane, the β5 
integrin and MerTK were expressed throughout the RPE cell in the mutant. 
Additionally, it was shown that the focal adhesion kinase (FAK) was localized to the 
basal side rather than throughout the RPE cells. These findings have led to the 
hypothesis that RPE cells are the specific cell type affected and the molecular 
mechanism might involve improper splicing of trafficking 
proteins79.This PRPF8 mutant phenotype has not yet been shown in humans and does 
not provide mutation-specific information.  
The patient mutation investigated here is a 6901 CàT missense mutation 
leading to a proline to serine substitution (P2301S) located in the Jab1/MPN domain 
in exon 42 of the C-terminal of PRPF8. A missense mutation at the same nucleotide 
position (P2301T) had previously been reported to cause RP1393. P2301S was first 
identified in a study of 43 Italian families and was later investigated in the context of 
the clinical phenotype of one Italian family94,95. The pedigree depicts a deceased male 
that had RP13 with two out of five children suffering from RP13, one of which was 
deceased and one of which harbored the P2301S mutation. Both of these individuals 
had children and grandchildren carrying the P2301S mutation, all exhibiting an RP13 
phenotype. The disease began with night blindness at an average age of 10.3 years 
(±6.4 SD). Fundus examination revealed atrophy of the retinal pigmented epithelium 
(RPE) in four living patients, but not in the two younger living patients. Testa et. al. 
concluded that this mutation results in a mild phenotype with partial preservation of 
cone photoreceptors, absence of rod photoreceptors, and atrophy or RPE94. It is 
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difficult to draw any conclusions about the precise cellular pathology from clinical 
phenotypes, but it is critical to note that both the RPE and rod photoreceptors are 
affected. Cellular modeling of RP13 is necessary to elucidate the cellular and 
molecular pathology of the disease. 
For the purpose of cellular modeling, the Pierce Lab of Harvard Eye and Ear 
Institute generously gifted RP13 patient fibroblasts to the Thomson lab of University 
of Madison, Wisconsin. The fibroblasts served as the somatic cell source for producing 
induced pluripotent stem cells via the Thomson factors: OCT4, SOX2, NANOG, and 
LIN2823. The patient harbors a P2301S mutation in the gene encoding the splicing 
factor PRPF8. To investigate the role of this mutation, Howden et. al. performed 
simultaneous reprogramming and correction of the missense mutations using 
CRISPR/Cas9 editing41,96,97.  The aim of this research is to produce RPE from the 
diseased and gene-corrected patient iPSC in order to investigate the cellular 
pathology. 
Next-generation sequencing can be used to perform non-Sanger, high-
throughput DNA and RNA sequencing, which is useful for screening multiple 
samples in parallel. In the context of retinitis pigmentosa, there are limitations to 
traditional methods of gene expression analysis, such as quantitative polymerase 
chain reaction (qPCR). Specifically, qPCR is limited to measuring the RNA expression 
of particular genes of interest; however, the genes needing to be investigated may be 
unknown in a novel disease model. RNA sequencing allows for the screening of 
diseased and gene-corrected patient-derived cells to identify genes of interest as well 
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as noncoding transcripts. Long noncoding RNA (lncRNA) or more specifically long 
intergenic non-coding RNA (lincRNA) are recently discovered RNA molecules. To 
narrow down the potential roles of lncRNA, these molecules are generally classified 
by their genomic context: (1) stand alone, (2) natural antisense transcripts, (3) 
pseudogenes, (4) long intronic ncRNA, or (5) divergent transcripts, promoter-
associated transcripts, and enhancer RNA98. Recent studies demonstrate that various 
lncRNA molecules may play a role in a healthy retina and contribute to retinal 
degenerative disease99–101.  
In addition to identifying non-coding transcripts, next-generation sequencing 
can help cluster differentially expressed genes based on their known functional role, 
such as a pathway analysis. Looking at the limited amount of differences in gene 
expression, we were able to identify REC8 and IRX5 which both have been shown to 
play a role in cell cycle regulation. Given the relationship between cell cycle regulation 
and ciliogenesis, we investigated this difference further.  
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Missense mutations at amino acid positions P2301S and H2309P have been 
identified in patients with splicing factor RP13.  
Figure 4. RP13 causative mutations in conserved Jab1/MPN domain of PRPF8. 
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B. Materials and Methods 
Sample Acquisition and Pluripotent Cell Line Maintenance 
Patient-specific human iPSC lines clone 3, clone 3.5, clone 3.80, clone 3.16, clone 
3.5, and clone 3.86.1 (gifts from S. Howden, collectively referred to as PRPF8 lines) 
were maintained in TeSR™-E8™ (StemCell Technologies, Vancouver, BC, Canada, 
http://www.stemcell.com) and passaged using an Versene (0.2g EDTA(Na4) per liter 
PBS) (Thermo Fisher) passaging protocol102. No manual dissection of undifferentiated 
colonies was necessary. All six PRPF8 lines were derived from fibroblasts isolated 
from the skin biopsy of one patient (gift from E. Pierce to J. Thomson).  The fibroblasts 
were reprogrammed using enhanced episomal vectors and corrected using Cas9 
protein and PRPF*-specific sgRNA41. 
H9 hESC (WiCell Research Institute, Madison, WI, http://www.wicell.org) 
and MyCell iPSC line no. 1013.201 (Cellular Dynamics International MyCell iPSC 
Services, Madison, WI, http://www.cellulardynamics.com) were adapted from 
mTESR™1 (StemCell Technologies) and manual passage to TeSR™-E8™ and Versene 
passage with manual dissection of differentiated colonies. All pluripotent cell lines 
were maintained on hESC-Qualified BD Matrigel (BD Biosciences, Sparks, MD, 
http://www.bdsciences.com) with daily medium changes and Versene passaging 
every 4-7 days. All cell lines were cryopreserved in 10% DMSO in TeSR™-E8™ at 
approximately 2x106 cells per mL.   
Maintenance of immortalized and primary cell lines 
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Primary human retinal microvascular endothelial cells (RMEC; Cell Systems, 
https://cell-systems.com/) were obtained at passage 4 and expanded to an intermediate 
cell bank at passages 7 and 9. RMEC were maintained on Matrigel (BD Biosciences) in 
microvascular endothelial cell media and passaged with trypsin (0.05%; Millipore 
Sigma, St. Louis, MO, http://www.sigmaaldrich.com) between days 3 to 5 before 
cells reached confluence. Immortalized human RPE, ARPE-19, were maintained in 
ARPE-19 media: DMEM/F12 with sodium pyruvate and 1X GlutaMAX (Gibco), 10% 
fetal bovine serum (Atlanta Biologicals, , Flowery Branch, GA, http://www.atlanta-
bioloigicals.com/), and 15 mM HEPES butter. Human fetal RPE (fRPE) (gift from P. 
Coffey) were maintained on Matrigel in RPE media103:  MEM - alpha modification 
(Millipore Sigma) supplemented with fetal bovine serum (5%, 15% for the first 3 days 
after seeding; HyClone), N1 (1X; Millipore Sigma), NEAA (1X), GlutaMAX-I (2 mM; 
Invitrogen), taurine (250 µg/mL; Millipore Sigma), triiodothyronine (0.013 µg/L; 
Millipore Sigma), hydrocortisone (20 ng/mL; Millipore Sigma).  
Differentiation of pluripotent cells to retinal pigmented epithelial cells 
PRPF8 iPSC lines and wild type iPSC MyCell and hESC H9 were seeded onto 
Matrigel-coated 6 well plates (Corning, Corning, NY, https://www.corning.com/) 
and cultured for 3 to 7 days before passage by Versene. Directed differentiation was 
initiated by Versene passage of undifferentiated stem cells to 12 well plates (Corning). 
Undifferentiated stem cells are left in small clumps rather than single cells, thus an 
exact seeding density of cells per cm2 is not possible. Instead, optimization of passage 
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was completed by a serial dilution of stem cells into a 12 well plate and examined for 
neural projections at day 4 of differentiation.  
Growth factors and small molecules were added over the course of fourteen 
days as previously described69: DMEM/F12 with 1X B27, 1X N2, 1X NEAA 
(Invitrogen, Carlsbad, CA, http://www.invitrogen.com), 50 ng/mL Noggin, 10 
ng/mL Dkk1, 10 ng/mL IGF1, 5 ng/mL bFGF (R&D Systems, Minneapolis, MN, 
http://www.rndsystems.com), 10mM nicotinamide (Millipore Sigma), 100 ng/mL 
Activin A (Peprotech, www.peprotech.com), 10µM SU5402 (Santa Cruz 
Biotechnology, www.scbt.com), and 10 µM CHIR99021 (Stemgent, 
www.stemgent.com). If necessary, cells with non-RPE morphology were manually 
dissected and removed at day 14. All remaining cells with RPE morphology were 
passaged using TrypLE (Invitrogen) for 5 minutes at 37 °C and 5% CO2 and passed 
through a strainer with 30 µm pores. Immature RPE were seeded on Matrigel-coated 
plates at density (1x105 cells per cm2) and allowed to mature for 4 to 5 weeks. RPE 
were matured and cryopreserved to create an intermediate cell bank as previously 
described104. 
Immunofluorescence  
iPS-derived RPE cells were thawed and seeded onto Matrigel-coated 
Permanox-treated 8-chambered slide. On day 30, cells were washed with phosphate-
buffered saline (PBS) and fixed in 4% paraformaldehyde (PFA) in 0.1M sodium 
cacodylate buffer, pH 7.4, for 15 minutes at 4 °C. Cells were washed twice with cold 
PBS then blocked with 5% bovine serum albumin (BSA) (Millipore Sigma) with 0.2% 
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Triton X-100 (Millipore Sigma) to permeabilize the cell membrane. After blocking, 
cells were incubated overnight at 4 °C with primary antibody. Cells were washed 
three times with cold PBS, incubated with the corresponding secondary antibody 
conjugated to AlexaFlour (1:300) (Invitrogen) or Cy2, 3, or 5 (1:200) (Jackson-Immuno) 
for 1 hr at 4 °C, incubated with Hoechst (2 µg/mL)(Invitrogen) for 5 min at room 
temperature, washed three times with PBS, mounted with 80 µL Prolong Gold 
Mountant (Invitrogen) and coverslip, and imaged on Olympus IX70 Inverted 
Compound microscope, Olympus Fluoview 1000 Spectral Confocal microscope 
(Olympus, Tokyo, Japan,  http://www.olympusamerica.com/), or Leica SP8 
Resonant Confocal microscope (Leica, Wetzlar, Germany, www.leica-
microsystems.com). 
Western Blot Analysis 
iPS-derived RPE were thawed and seeded at 1.5x105 cells per cm2 in duplicate 
on Matrigel-coated 6-well plates (Corning). RPE were allowed to mature for 30 days 
and then were passaged using TrypLE (Gibco). An average of 1.5x106 cells were 
collected from each well and pelleted by centrifugation at 2500 x g for 5 minutes. The 
supernatant was discarded, and the cells were washed twice in cold PBS and pelleted 
by centrifugation. Cells were lysed using RIPA lysis buffer (Thermo Scientific) at a 
concentration of 1 mL of buffer for 5x106 cells as per manufacturer’s 
recommendations, with 1X final concentration of Halt Protease Inhibitor Cocktail and 
Halt Phosphatase Inhibitor Cocktail (Thermo Scientific). The cell buffer mixture was 
 46 
shaken gently on an orbital shaker for 15 min at 4 °C and then centrifuged at 14,000 x 
g for 15 minutes. Supernatant was collected and stored at -80 °C.  
Protein concentration was determined using a Pierceä BCA Protein Assay Kit 
(Thermo Fisher Scientific) according to the manufacturer’s microplate procedure 
(Synergy H1 Hybrid Multi-Mode Reader, BioTek, Winooski, VT, 
http://www.biotek.com/). Cell lysates (10-20 µg total protein per lane) were 
separated by sodium dodecyl sulfate polyacrylamide gel electrophoreses (SDS-
PAGE) in Novex™ WedgeWell™ Tris-Glycine Gels (Invitrogen). Separated proteins 
were transferred to nitrocellulose membranes with 0.45 µm pore size (Life 
Technologies) using Pierce™ Power Blotter semi-dry transfer, blocked for 1 hour at 
room temperature in Blocking Buffer for Fluorescent Western Blotting (Rockland, 
Pottstown, PA, http://www.rockland-inc.com/), and incubated with primary 
antibodies overnight at 4 °C: monoclonal mouse anti-GAPDH loading control (0.5 
µg/mL; MA5-15738); polyclonal rabbit anti-PRPF8 (1 µg/mL; ab87433 and ab79237). 
Membranes were washed with Tris-Buffered Saline Tween-20 (TBST) (Thermo Fisher 
Scientific), probed with secondary antibodies for 30 minutes at room temperature: 
donkey anti-mouse IgG (H+L) (IRDye® 680RD; 0.06 ng/mL; LI-COR Biosciences, 
Lincoln, NE, http://www.licor.com/) and donkey anti-rabbit IgG (H+L) (IRDye® 
800CW; 0.06 ng/mL), and washed with TBST. Fluorescent signal was visualized on 
an Odyssey Imager (LI-COR Biosciences). 
Quantitative PCR Analysis 
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Passage 3 iPS-derived RPE were thawed and seeded at 1.5x105 cells per cm2 onto 
Matrigel-coated 6-well plates (Corning). RPE were allowed to mature for 30 days and 
then were passaged using TrypLE (Gibco). Cells were collected by centrifugation at 
2500 x g for 5 min. Cells were lysed using Buffer RLT (RNEasy Mini Kit, Qiagen) at a 
concentration of 350 µL per 1x106 cells. cDNA was synthesized by two methods. Up 
to 1 µg of total RNA was used to synthesize cDNA using the iScript cDNA Synthesis 
Kit (Bio-Rad, Hercules, CA, http://www.biorad.com/). Alternatively, 30 ng of RNA 
was used to synthesis cDNA using AgPath-ID™ One-Step RT-PCR Reagents. Primers 
used were TaqMan Gene Expression Assays (Thermo Fisher). Quantitative real-time 
polymerase chain reaction was performed using CFX96™ Real-time PCR Detection 
System (Bio-Rad) using FAM detection. 20 µL reactions were run in triplicate in a 96-
well plate. Data were normalized by two methods: the geometric mean of 
housekeeping genes SERF2, EIF2B2, and UBE2R2 or by the Livak method105.  
ELISA Assay for PEDF and MFG-E8 
Passage 3 iPS-derived RPE, fetal RPE, ARPE-19, and RMECs were thawed and seeded 
at 1.5x105 cells per cm2 in triplicate onto Matrigel-coated 24-well Transwell® inserts 
(Corning). Cells were allowed to mature for 30 days and media was collected 48 hours 
after the last media change from the apical and basal compartments. Media samples 
were then flash frozen in liquid nitrogen and stored at -80 °C. Secreted protein was 
measured using enzyme-linked immunosorbent assays as per manufacturer’s 
recommendations for pigment epithelial derived factor (Human PEDF ELISA Kit, 
BioProductsMD, Middletown, MD, http://www.bioproductsmd.com/) and milk-fat 
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globule-EGF factor 8 (Human MFG-E8 Quantikine ELISA Kit, R&D Systems, 
Minneapolis, MN, http://rndsystmes.com/). Optical density was measured using a 
fluorescent plate reader (Synergy H1 Hybrid Multi-Mode Reader).  
Phagocytosis Assay 
Passage 3 iPS-derived RPE, fetal RPE, ARPE-19, and RMECs were thawed and seeded 
at 1.5x105 cells per cm2 in quadruplicate onto Matrigel-coated 96 well plates (clear 
bottom, black walls) (Corning). Cells were allowed to mature for 30 days and then 
were challenged with approximately 10 FITC-labeled (Invitrogen) photoreceptor 
outer segments (POS) (InVision BioResources, Seattle, WA, 
http://www.invisionbio.com/) per cell for 5 hr. Excess POS were aspirated and the 
cells were washed for 1 min three times with room temperature PBS. Subsets of 
samples were treated with 0.4% Trypan blue (Fisher Scientific) for 10 min at room 
temperature to quench FITC fluorescence. All samples were washed twice with PBS, 
fixed with ice-cold 100% methanol (Millipore Sigma), and rehydrated with PBS for 
overnight incubation. Fluorescence was quantified using FITC detection (excitation 
488 nm, detection 520 nm) (Synergy H1 Hybrid Multi-Mode Reader, BioTek, 
Winooski, VT, http://biotek.com/). All fluorescent detection was normalized to 
AREPE-19 controls.  
RNA Sample Collection  
 
Passage 3 iPS-derived RPE were thawed and seeded at 1.5x105 cells per cm2 onto 
Matrigel-coated 6-well plates (Corning). RPE were allowed to mature for 30 days and 
then were passaged using TrypLE (Gibco). Cells were collected by centrifugation at 
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2500 x g for 5 min. Cells were lysed using Buffer RLT (RNEasy Mini Kit, Qiagen) at a 
concentration of 350 µL per 1x106 cells. 
RNA-Sequencing Library Preparation  
Total RNA was processed for library preparation using Illumina TruSeq® RNA 
Sample Preparation kit as per manufacturer’s recommendations and sequenced on 
Illumina HiSeq 4000.  
RNA-Sequencing Data Analysis  
RNA-sequencing reads were aligned to the reference human genome (GRCh37) using 
Rsubread TopHat Alignment. The resulting count matrix was analyzed for 
differential expression in the Bioconductor package edgeR for differential 
expression107.  
siRNA knockdown of PRPF8 and LOC339975 
Passage 3 iPS-derived RPE were thawed at seeded at 60-80% of confluence in 
Matrigel-coated 24-well plates. Each cell line was plated in duplicate. 24 hours post 
seeding 1pmol of siRNA in OptiMEM media (Gibco) with lipofectamine (Gibco) for 
each siRNA, specifically PRPF8 (Invitrogen), LOC339975, and a negative siRNA 
control were added to the cells. 72 hours post-seeding cells were harvested using 
TrypLE (Gibco) and total RNA was collected for qPCR analysis.  
Cell Cycle Analysis 
RPE were enzymatically passaged at various time points and fixed in 
4%paraformaldehyde in sodium cacodylate buffer, pH 7.4. Cells were permeabilized 
and blocked in 0.1% Triton-X in 0.5% bovine serum albumin in PBS. Flow cytometry 
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samples were prepared with 1 x 106 cells in suspension. Samples were incubated for 
30 min at room temperature in the dark with 0.5 mL of FxCycle™ PI/RNase Staining 
Solution (Life Technologies). Samples were analyzed without washing using 488-nm 
excitation on an Accuri C6 Flow Cytometer (BD Biosciences).  
Statistical Analysis 
For all experiments, two-way ANOVA tests were performed. Significance was 
determined at p < 0.05. 
C. Results 
Characterization of RPE  
To validate the production of RPE from all patient-derived iPSCs, the 
characterization of the cells was performed by established methods67,69. The purity of 
the RPE population after differentiation was determined by quantifying PMEL17 
expression via flow cytometry (Figure 5). To analyze the expression of retinal specific 
genes, quantitative polymerase chain reaction was performed for several genes. RPE 
cell genes included BEST1, RPE65, PMEL17, CRALBP, and MITF isoform 2. 
Undifferentiated stem cell genes and proliferation marker included REX1, SALL, and 
MKi67. Non-RPE genes included S100A4, ITGA2, MITF isoform 4+5, PECAM1, and 
MAP2. Housekeeping genes included EIF2B2, UBE2R2, and SERF2. All six patient-
derived iPSC cell lines were differentiated into RPE that expressed all native RPE 
genes by passage 0 day 30 or sooner and no longer expressed stem cell or proliferation 
markers (Figure 5). Interestingly, the only non-RPE gene expressed after 
differentiation was low levels of S100A4, a calcium-binding protein specific to 
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fibroblasts108. This may be related to the use of patient fibroblasts as the origin of 
somatic cells for reprogramming.  
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Figure 5. Purified population of PMEL+ RPE and relevant gene expression. 
Flow cytometry analysis of RPE at passage 0 day 30 RPE reveal a population 
of PMEL+ cells compared to the unstained or IgG control. PCR analysis of 
relevant RPE genes reveal similar levels of expression relative to housekeepers 
and minimal expression of non-RPE genes.  
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To observe the localization of native RPE proteins, PMEL17, BEST1, and ZO-1 
were examined by immunocytochemistry. Premelanosome 17 (PMEL17) is a 
transmembrane glycoprotein that is expressed early in pigmented cells and serves as 
an early marker of RPE differentiation68. Bestrophin 1 (BEST1) is an integral 
membrane protein that functions as a calcium-activated chloride channel in which 
mutations are known to cause retinal degeneration109. Zonula occludens (ZO-1) is a 
tight junction complex that helps establish the integrity of  the epithelial monolayer. 
Diseased and corrected RPE expressed these RPE proteins in the proper locations 
(Figure 6). Localization of PRPF8 was also observed and confirmed to localize to the 
nucleus with some potential localization in speckles outside the nucleus.  
The secretion of pigment epithelium-derived factor (PEDF) was measured by 
enzyme-linked immunosorbent assay (ELISA). The RPE are grown on Transwell® 
inserts to allow the separation of apical and basal media. For each of the six patient-
derived lines, the apical media contained a significantly higher concentration of PEDF 
than the basal media, indicating the proper polarity of the iPSC-derived RPE (Figure 
7). The secretion of milk-fat globule-EGF factor 8 protein (MFG-E8) was measured by 
ELISA and compared to the same positive and negative control cell lines used in the 
phagocytosis assay. There was no significant difference between diseased and 
corrected RPE, but both secreted significantly more MFG-E8 than the positive controls 
(fetal RPE and immortalized ARPE-19) and the negative control, retinal microvascular 
endothelial cells.  
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Immunocytochemistry revealed proper localization of RPE-specific proteins 
(premelanosome 17, bestrophin 1, and zonula occludens). PRPF8 nuclear 
localization in both diseased and corrected cells. Scale bar equals 100 um. 
Figure 6. Localization of RPE-specific proteins. 
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Apical Secretion of 
MFG-E8 
Diseased and corrected RPE establish apicobasal polarity as indicated by 
secretion of PEDF. Both diseased and corrected RPE secrete significantly higher 
levels of MFG-E8 than the positive and negative control cell lines.  
Figure 7. Secretion of functional proteins in RPE. 
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Patient-derived RPE are not deficient in phagocytosis 
 Phagocytosis was measured by challenging the iPSC-derived RPE with 
fluorescently labeled photoreceptor outer segments and quantifying the fluorescence. 
Previous methods involved purification of outer segments from whole bovine eyes. 
The outer segments used in these experiments were purchased commercially to 
ensure the structural integrity and purity of the outer segments. After five hours of 
incubation, the relative fluorescent units were measured at an excitation of 488 nm. 
The total fluorescence is considered both the bound and ingested outer segments. A 
duplicate plate of cells was incubated with Trypan blue without permeabilization to 
quench fluorescence of any bound outer segments that were not ingested. The results 
indicate that the diseased and gene-edited cells were able to bind and ingest outer 
segments significantly more that the negative control line, retinal microvascular 
endothelial cells. Previous methods had required normalization of the data to show a 
significant difference from the negative control, which we attribute to endocytosis of 
sheared outer segments isolated from whole eyes. Since both lines bound and ingested 
significantly less than the immortalized ARPE-19, the assay was repeated in 
comparison to three wild-type stem cell-derived RPE. All six of the patient-derived 
lines and the three wild-type (H9 hESC, UCSF4 hESC, and MyCell iPSC) were 
produced from the same differentiation batch and are shown to phagocytose similar 
levels of outer segments (Figure 8).  
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Diseased and corrected RPE were able to phagocytose outer segments in both 
binding and ingesting phases as well as fetal RPE and significantly more than 
endothelial cells (RMEC). 
Figure 8. Phagocytosis of photoreceptor outer segments. 
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Atrophy of RPE upon extended passage  
 As a preliminary investigation of atrophy, RPE were passaged continuously 
for 100 days to observe the decline in the number of cells yielded per cm2. After the 
initial seeding at 1 x 105 cells per cm2, the RPE were able to reach a density of up to 3 
x 105 cells per cm2, indicating that the cells underwent approximately 1 to 2 divisions. 
After six passages, the cell yield started to decline to 2.5 x 105 cells per cm2, and by 
day 100, the RPE maintained the initial seeding density, indicating that there was no 
proliferation occurring. We determine that within 100 days, there was no significant 
difference in the ability of the diseased and corrected RPE to proliferate (Figure 9).  
 Cells were imaged before passage to observe morphology and pigmentation 
(Figure 10-11). As shown, diseased and corrected cells were able to maintain some 
level of cuboidal morphology and pigmentation throughout the passages. However, 
holes and fibroblastic cells started to appear after several passages and pigmentation 
was sparse (Figure 9). The images shown are meant to be representative, but an 
unbiased quantification of morphology and pigmentation would be required to draw 
any conclusions from the cell culture images. As a first estimation, we have relied on 
cell count to estimate proliferation and atrophy of RPE.  
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Figure 9. Atrophy of RPE upon extended passage. 
RPE were passaged enzymatically at a seeding density of 1 x 105 cells per cm2  
and allowed to grow for 5 to 30 days. Both diseased and corrected RPE were able 
to proliferate until day 100. Each time point consists of two separate wells for all 
six cell lines.  
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Figure 10 Extended passage RPE maintained epithelial morphology and 
confluence. 
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Figure 11. Extended passage RPE maintained pigmentation. 
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Confirmation of corrected point mutation in RPE 
The mutated region of the PRPF8 gene was sequenced to confirm 
CRISPR/Cas9 correction of the P2301S point mutation. Figure 12 depicts the gene-
corrected cell lines are homozygous for cytosine at position 6901 whereas the diseased 
cell lines are heterozygous for cytosine and thymine.  The repair template contained 
silent mutations as indicated in the gene-corrected lines. These silent mutations, 
histidine(2306) and serine (2312) residues downstream of patient-specific mutation, 
aide in screening for off-target effects and prevent Cas9 re-cutting following gene 
repair and for confirming each cell line is derived from one clonal population. These 
silent mutations are predicted to be within a splice site 
Minimal differentially expressed genes  
 Diseased and gene-corrected cell lines were grouped for analysis of 
differentially expressed genes using edgeR (Figure 13-14). Lowly expressed genes 
were filtered out by eliminating any sequences with less than 1 count per million 
(CPM) and the counts were normalized using a trimmed mean of M-values (TMM)110. 
Statistical dispersion was estimated using the quantile-adjusted conditional 
maximum likelihood (qCML) method. Biological coefficient of variation (BCV) was 
calculated and a multi-dimensional scaling (MDS) plot was produced to help identify 
outliers. Differential genes with a false detection rate (FDR) less than 0.05 were 
identified.  
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Figure 12. Confirmation of corrected point mutation in RPE and identification 
of outliers. 
 Sequencing of PRPF8 revealed the corrected genes received the point correction 
as indicated by the silent mutation (GCT) whereas the diseased lines retain 
different nucleotides on each chromosome (A and G). Corrected and diseased 
lines do not cluster but 3.8 and 3.5 are possible outliers. FC=fold-change, 
dim=dimension.  
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Figure 13. Differential expression of genes in passage 3 RPE from a single 
patient. 
 Eight genes identified with IRX5, A2M, and NRCAM more highly expressed in 
the corrected cells and LOC339975, CNTN4, DPP6, FAM135B, and REC8 more 
highly expressed in diseased cells. FC=fold-change, CPM=counts per million.  
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Figure 14.  Differential expression of genes without outliers. 
 Differential expression analysis was repeated with and without clones 3.8 
(corrected) and 3.5 (diseased). REC8 is identified in both analyses.  
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In the MDS plot, the distances between samples corresponds to the biological 
variation between those samples, which allowed for the identification of clone 3.8 as 
a possible outlier. There is no clear separation between the diseased lines (clone 3, 3.5, 
and 3.80) compared to the gene-corrected lines (clone 3.16, 3.8, and 3.86.1). In the log 
fold-change plot, the eight red points indicate the differentially expressed genes.  
Upregulation of lncRNA in mutated retinal pigmented epithelial cells  
 In two RNA-sequencing experiments, LOC339975 was upregulated in the 
diseased retinal pigmented epithelial cells. In comparing the two groups, LOC339975 
was expressed log fold-change of 4 higher in the mutated cell lines. This was 
confirmed by quantitative PCR analysis using probes for LOC339975.  
 To determine if LOC339975 is expressed in immature RPE and induced 
pluripotent stem cells, PMEL, TYRP1, and LOC339975 were measured in passage 0 
day 30 RPE and SALL4, REX1, and LOC339975 were examined in passage 12 day 5 
iPSC. In iPSC, immature, and mature RPE, the lncRNA is expressed at significantly 
higher levels in the diseased cells that the gene-corrected when compared to wild-
type cells.  
  siRNA-mediated knockdown was performed to observe the effects of PRPF8 
knockdown on the expression of lncRNA and to confirm aberrant expression of 
LOC339975 via RNA-specific targeting. PRPF8-siRNA decreased RNA expression in 
diseased and corrected cell lines when compared to a negative control-siRNA in the 
same cell lines. LOC339975-siRNA had no effect on PRPF8 expression and was 
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effective in decreasing expression of the lncRNA in diseased cells. There was no 
detection of LOC339975 in the corrected cell lines (Figure 15).  
  
Figure 15. Detection of lncRNA in iPS and immature RPE. 
PCR analysis of iPS and RPE from diseased and corrected lines reveal no 
significant difference of stem cell and RPE-specific genes but significant 
expression of lncRNA is observed in diseased cells when normalized to wild-
type iPS and RPE. siRNA knockdown was successful for both lncRNA and 
PRPF8 when normalized to a negative control siRNA.   
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From this analysis, we demonstrate the lncRNA is upregulated in cells 
harboring a missense mutation in PRPF8 that is known to cause autosomal dominant 
retinitis pigmentosa. The role of lncRNA in splicing factor retinitis pigmentosa has 
not been reported prior to these studies. 
The variation analysis as demonstrated that diseased clone 3.5 and corrected 
clone 3.8 were potential outliers, thus the differential expression analysis was 
performed with and without these outliers. In both analyses, REC8 was aberrantly 
expressed in the diseased RPE at a high level as indicated by logCPM (counts per 
million). Upon further investigation, it was found that REC8 inhibits the G0/G1 to S 
phase transition, and IRX5, a transcription factor more highly expressed in the 
corrected cells, promotes the G0/G1 to S phase transition. This led to the investigation 
of cell cycle arrest in the diseased cells. 
The cell cycle analysis is based on the principal that the fluorescent intensity of 
propidium iodide at 488 nm is directly proportional to the mass of DNA present, 
which is expected to be higher in S phase and G2 phase than G0/G1 due to the 
replication of chromosomes. RNase is used to destroy RNA present to ensure 
fluorescence is only from the DNA. As expected, there are no cells in G2 phase at day 
30, but the data revealed that a disproportionate number of cells were in the G0/G1 
phase (Figure 16). 
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Figure 16. Increased population of G0/G1 phase in diseased state. 
Flow cytometry analysis using propidium iodide and RNase reveal the 
proportion of cells in G0/G1 phase versus S phase. The same number of events 
were collected for each sample and the resulting counts were quantified in terms 
of cell distribution.  
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D. Discussion  
With this work, we demonstrate that iPSC-derived RPE from a patient, with 
and without gene-correction, can produce a purified population of RPE that recreates 
the gene and protein expression of native RPE. In order to elucidate the pathology of 
splicing factor retinitis pigmentosa as caused by P2301S point mutation in PRPF8, it 
is important to ensure that the cells being examined recapitulate the in vivo cells.   
After differentiation to a specific cell type, there are several general methods 
used to confirm the purity and functionality of the cell type of interest: 1) genetic 
analysis by polymerase chain reaction or next-generation sequencing, etc. 2) protein 
analysis by western blot, enzyme-linked immunosorbent assay, fluorescence assisted 
cell sorting, etc. 3) functional analysis such as photoreceptor outer segment 
phagocytosis. The same methods that have been used to confirm differentiation of a 
particular cell type may also be used to look for abnormalities in a disease state. While 
it would have been useful to find a difference between the diseased and corrected 
RPE, it is unsurprising that these assays did not reveal any distinction. There is no 
evidence that a mutation in PRPF8 affects the expression of RPE-specific genes or 
protein localization and secretion. There was a mouse model that argued that the 
protein localization of integrin subunits was affected in a knockout mouse for PRPF8, 
PRPF31, and PRPF38. Specifically, they argue the αV integrin subunit, but note the β5, 
was mislocalized in the mutants. However, this result was a qualitative observation 
and the fluorescent images do not appear to support their argument.  
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The reproducibility of differentiation protocols is vitally important to the 
success of disease modeling. In order to draw conclusion from any observed 
differences between cells, there must be a strong indication that the cell populations 
are similar by other measurements, especially considering the concerns about line to 
line variability47. Once the gene expression and protein localization and secretion had 
been established, functional assays that have been shown to play a role in disease can 
be observed. RPE phagocytose POS on a daily basis, which is critical to the health of 
the retina65. The phagocytic relationship between RPE and photoreceptor outer 
segments was first observed by autoradiography over forty years ago111. Modern 
methods utilize the ability of RPE to phagocytose as a measurement of RPE health 
and differentiation efficiency in vitro112. RPE phagocytose via specific integrin 
subunits and are significantly more active in phagocytosis than most other cell types, 
allowing researchers to definitively identify RPE in culture78,113.  Quantification of 
phagocytosis has been examined by several methods, including pixel detection and 
fluorescence plate reader114.  
 Farkas et.al. argued that phagocytosis was deficient in the mutant RPE after 
isolation from the mice, which remained to be shown in human cells8. The mutation 
that was introduced in the mouse model (H2309P) was in the same domain as the 
patient cells (P2301S) (Figure 4). In fact, this sub region of the Jab1/MPN domain of 
PRPF8 is highly conserved across species and contains seven amino acids that have 
been recorded to have disease-causing point mutations88,92,93. The highly conserved 
nature of these residues suggests their critical role in the ill-defined function of PRPF8. 
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In order to assess phagocytosis, optimizations were required to observe a significant 
difference between the stem-cell derived RPE and the negative control cell line. 
Previous attempts of our phagocytosis assay were performed with preparations of 
photoreceptor outer segments that were isolated from whole bovine eyes in full light. 
The resulting preparations resulted in bleached outer segments, whereas 
commercially available outer segments retained the color of the tissue as it was 
isolated under low light conditions. Furthermore, the fluorescent labeling was 
performed at centrifugation speeds that have been reported to shear outer segments. 
By reducing the centrifugation speeds as described in the detailed protocol, outer 
segments were shown to retain their rod-like morphology. We believe this reduction 
in bleaching and shearing allowed there to be a significant difference between the 
negative cell line (retinal microvascular endothelial cells) and the stem cell derived 
RPE.  
 The secretion of pigment epithelium derived factor is frequently used as a 
measurement of apicobasal polarity and maturity of the RPE. We also wanted to 
investigate the secretion of MFG-E8, which is more closely related to the phagocytic 
function of RPE and had not been previously measured in stem cell-derived RPE. 
There was no significant difference in the ability of diseased and corrected RPE to 
secrete PEDF, and when compared to negative controls, stem cell derived RPE 
secreted significantly more MFG-E8, as expected. We believe that secretion of MFG-
E8 and other proteins directly related to phagocytic function may help elucidate 
pathology of phagocytic defects in other disease models.   
 72 
In addition to requiring robust differentiation procedures to produce a 
homogeneous population of RPE and optimization of functional assays, the initial 
reprogramming of the patient fibroblasts into iPSC must also be robust. Due to the 
relative simplicity and high efficiency, CRISPR/Cas9 has been used increasingly for 
genetic modifications in stem cells. Howden et. al. has developed an efficient protocol 
for the generation of gene-corrected cells lines that undergo the more precise 
homology directed repair pathway (HDR) rather than the predominate yet more 
mutative non-homologous end joining (NHEJ)30,115. The CRISPR/Cas9 system 
developed by Howden et al. and used to edit the cells in this study relies on two key 
factors related to the cell cycle: (1) cells prefer NHEJ in G1 phase and HDR in S phase, 
and (2) fusion of Cas9 endonuclease and geminin protein (Cas9-Gem) can be used to 
degrade Cas9 in the beginning of G1 phase. This allows the simultaneous 
reprogramming and gene editing of patient fibroblasts with a two to three-fold 
decrease in NHEJ and a reduction of insertion/deletion mutations in the healthy 
allele115. 
In disease modeling, it is critical to precisely edit a gene in order to compare 
the diseased and gene-corrected cells in a way that recapitulates the cellular and 
molecular mechanisms of the disease.  The simultaneous reprogramming and gene-
correction method allowed for the production of six passage-matched clones from one 
biological replicate. Due to the robust reprogramming and differentiation procedures, 
the next-generation sequencing transcriptome analysis revealed minimal 
differentially expressed genes. In two repeated RNA sequencing experiments, it was 
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found that a long-noncoding RNA (LOC339975, henceforth referred to as lncRP13) 
was expressed in the diseased cells but not the gene-corrected cells. As shown in the 
BCV analysis, clone 3.8 was identified as an outlier and was the most difficult to 
differentiate based on morphological assessment during the 14-day protocol. In 
examining the raw data, clone 3.8 was usually an outlier in the differentially expressed 
genes with the exception of lncRP13. Aberrant expression of lncRP13 was confirmed 
by quantitative polymerase chain reaction for all six of the patient-derived clones and 
normalized to passage-matched healthy control induced pluripotent stem cell line.  
We hypothesized that knockdown of PRPF8 in gene-corrected cell lines may 
induce expression of lncRP13. Our results indicate that upon small interfering RNA 
(siRNA) knockdown of PRPF8, there is no detectable expression of lncRP13. These 
data suggest that the aberrant expression of lncRP13 is a result of the patient-specific 
mutation and is not due to a decrease in PRPF8 expression. Furthermore, we 
demonstrate that siRNA-mediated knockdown of lncRP13 in the diseased cells 
provides further evidence of the expression of this lncRNA. Future studies may 
demonstrate the functional role of lncRP13 in splicing factor retinitis pigmentosa, and 
siRNA-mediated knockdown may provide a tool for investigating the pathology or 
development of a drug therapy. 
LncRNA has been implemented in its role in the normal function of the retina 
as well as in disease states99–101. lncRP13 specifically has remained uncharacterized. 
LncRNA has been shown to interact with proteins in involved in several different 
pathways116. Given the RNA binding ability of PRPF8, we hypothesize that there may 
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be a direct interaction between PRPF8 and lncRP13; however, understanding the RNA 
biology of lncRNA has proven difficult117. Future studies examining the interaction of 
lncRNA with pre-mRNA processing factors may help elucidate the role of lncRP13 in 
the molecular pathology of autosomal dominant retinitis pigmentosa.  
Our RNA sequencing analysis also revealed that the diseased cells were more 
highly expressing REC8, which had been shown to inhibit cell cycle progression in 
other cell types but had not been studied in RPE118. Further investigation of the role 
of cell cycle arrest in inherited retinal degenerations led us to a body of literature 
pertaining to cell cycle, ciliogenesis, and ciliopathies.  
Ciliopathies are a growing class of inherited retinal diseases that result in 
atrophy of the photoreceptors and the retina119. An siRNA-based functional genomics 
screen identified 112 candidate genes for their involvement in growth and 
maintenance of primary cilium120. Among these candidates were three pre-mRNA 
processing factors: PRPF6, PRPF8, and PRPF31, mutations in which can cause 
autosomal dominant retinitis pigmentosa. A more recent siRNA study investigated 
the connection between ciliogenesis and cell cycle progression, finding that PRPFs 
function in disassembly of the primary cilium and progression of cell cycle121. 
Together these data led us to hypothesize that PRPF8 may function beyond splicing 
in the disassembly of cilium and cell cycle progression.  
Our results demonstrate that a larger proportion of diseased cells are arrested 
in the G0/G1 phase as compared to corrected cells. This work is the first report of cell 
cycle arrest in patient-derived cells as compared to those subjected to siRNA 
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knockdown of PRPFs. Future work should be directed towards identifying the precise 
functional role of PRPF8 and the other pre-mRNA processing factors in cell cycle 
regulation and ciliogenesis. Researchers have shown that RPE and retinal organoids 
can be used to examine the morphology of primary cilium in both photoreceptors and 
RPE36,59. This work pertained to mutations in CEP290, which had previously been 
shown to cause fewer cilia in fibroblasts from patients35. Given the role of CEP290 in 
ciliogenesis and the potential role of PRPFs in cilia disassembly, future studies will 
need to determine how to quantify abnormal cilia morphology depending on the 
patient-specific pathogenesis.  
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E. Conclusions 
Our findings demonstrate that mature, functional RPE can be differentiated 
reproducibly from six induced pluripotent stem cells lines. This work shows that 
previous reports of phagocytic defects in mouse RPE are not detected in a human 
model of RP13. This is the first report that PRPF8 diseased RPE aberrantly express the 
lncRNA LOC339975 that is susceptible to siRNA. Earlier work has investigated the 
role of PRPF8 in binding RNA as well as the suspected role of lncRNA in retinal 
degeneration. Genetic correction of the PRPF8 mutation restored the expression of 
lncRNA to the level of wild-type cells. Future studies will help elucidate the role of 
this lncRNA in the pathology of splicing factor retinitis pigmentosa. Finally, diseased 
RPE aberrantly express REC8, which is thought to regulate the G0/G1 to S phase 
transition, and a disproportionately large population of diseased RPE are in the 
G0/G1 phase as determined by DNA mass.  
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IV. Differentiation of Induced Pluripotent Stem Cell-Derived Retinal 
Organoids for Modeling Autosomal Dominant and Autosomal Recessive Retinitis 
Pigmentosa 
 
ABSTRACT 
Retinitis pigmentosa can be inherited in autosomal dominant and recessive 
patterns. Specifically, mutations in ubiquitously expressed splicing factor proteins are 
known to cause an autosomal dominant form of the disease, whereas mutations in the 
retina-specific crumbs 1 (CRB1) protein cause an autosomal recessive form of the 
disease. In this study, we investigated the use of stem cell-derived retinal organoids 
for modeling two forms of retinitis pigmentosa. We show that retinal organoids 
produced from patient-derived induced pluripotent stem cells are morphologically 
similar to wild-type retinal organoids in vitro. Furthermore, we demonstrate that 
retinal organoids produced from wild-type stem cells express CRB1. Expression of 
neural retina-specific proteins, including vimentin and rhodopsin, were observed. 
Functionally, the diseased and gene-corrected retinal organoids were able to achieve 
organoid growth rates comparable to those seen in wild-type retinal organoids. These 
studies show that patient-derived and wild type stem cells are able to differentiate 
into retinal organoids that recapitulate in vivo development, including expression of 
proteins that are known to cause retinitis pigmentosa.   
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A. Autosomal dominant splicing factor retinitis pigmentosa: PRPF8  
1. Introduction 
The human retina consists of not just a few types of neurons, but rather is made 
up of around 55 different cell types. Masland et al. 2001 describes the added 
complexities of the primate retina, which unlike some simpler mammals, consists of 
two types of horizontal cells, twenty-nine types of amacrine cells, between ten and 
fifteen different retinal ganglion cells, and so on1. The inherent complexity of the 
retina has made it challenging to develop retinal organoids that recapitulate the native 
retina. The success of existing disease models suggests it is not necessary to produce 
all of these cell types in a way that mimics the positions and proportions they are 
found in vivo.  Instead, protocols have focused on development of the two most 
commonly affected cell types: photoreceptors and RPE. Production of neural retina 
has been approached in both two-dimensional 49,50 and three-dimensional methods 51–
54. Various methods for directing differentiation of neural retina  in both two-
dimensional and three-dimensional cultures for human and mouse stem cells has 
been thoroughly reviewed from 2006 through 2017 55.  
 Here we describe the process used to establish a three-dimensional retinal 
organoid model from patient-derived iPSC. The iPSC result from a novel method of 
simultaneous reprogramming and gene-correction, making this is the first report of 
retinal organoids produced from such cells and from a patient with PRPF8 splicing 
factor retinitis pigmentosa. 
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2. Materials and Methods 
Differentiation of pluripotent cells to retinal organoids 
PRPF8 iPSCs and wild type MyCell iPSCs and H9 hESCs were seeded onto 
Matrigel-coated 6 well plates (Corning) and cultured for 3 to 7 days before passage by 
Versene to micro-space 96 well plate (Elplasia, Tokyo, Japan, 
http://www.elplasia.com) for embryoid body formation. Neural induction and 
retinal differentiation were performed as described in Zhong et al. 2014 52. Media 
formulations included neural induction media (NIM) and retinal differentiation 
media 1, 2, and 3. NIM consisted of 1:1 DMEM:F12, 1 X N2, 1 X NEAA, and 2 µg/mL 
heparin (STEMCELL Technologies). RDM1 was used from day 16 to day 28 and 
consisted of 3:1 DMEM:F12 1 X B27 without Vitamin A, 1 X NEAA. RDM2 consisted 
of 3:1 DMEM:F12, 1X B27, 1X NEAA, and RDM3 consisted of 3:1 DMEM:F12, 1 X B27, 
1 X NEAA, 10% fetal bovine serum (Atlanta Biologicals), 100 µM taurine, and 2 µM 
GlutaMAX (Fisher Scientific).  
Cryosectioning  
  Retinal organoids (ROs) were removed from suspension culture between days 
40 and 180. Individual ROs were placed in single wells of a 24 well plate and fixed in 
4% paraformaldehyde (PFA) in 0.1M sodium cacodylate buffer, pH 7.4, for 20 minutes 
at room temperature on an orbital shaker in the dark. Samples were imaged and 
stored for up to 1 month in 0.1% PFA. Fixed samples were rinsed three times for 5 min 
in cold PBS and cryoprotected in a sucrose gradient: 10%, 20%, and 30% sucrose in 
PBS for 1 hr each followed by 40% sucrose in PBS overnight on an orbital shaker. 
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Samples were placed in disposable plastic molds, embedded in Optimal Cutting 
Temperature Compound (OCT, Fisher Scientific, Hampton, NH, 
http://www.fishersci.com/), and frozen on dry ice to store at -80 °C. Frozen samples 
were cut into 10-20 µm sections on a Leica Cryostat CM1850 (Leica, www.leica-
microsystems.com) at -20 °C and adhered to SuperFrost Plus Microscope Slides 
(Fisher Scientific). 
Immunofluorescence 
  
  Retinal organoid samples were washed twice with cold PBS then blocked with 
5% bovine serum albumin (BSA) (Millipore Sigma) with 0.2% Triton X-100 to 
permeabilize the cell membrane. After blocking, ROs were incubated overnight at 4 
°C with primary antibody. Cells were washed three times with cold PBS, incubated 
with the corresponding secondary antibody conjugated to AlexaFlour (1:300) 
(Invitrogen) or Cy2, 3, or 5 (1:200)(Jackson-Immuno) for 1 hr at 4 °C, incubated with 
Hoechst (2 µg/mL)(Invitrogen) for 5 min at room temperature, washed three times 
with PBS, mounted with 80 µL Prolong Gold Mountant (Invitrogen) and coverslip, 
and imaged on Olympus IX70 Inverted Compound microscope, Olympus Fluoview 
1000 Spectral Confocal microscope (Olympus, www.olympusamerica.com), or Leica 
SP8 Resonant Confocal microscope (Leica, www.leica-microsystems.com). 
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3. Results 
Characterization of retinal organoids  
 
 Patient-derived iPSC were differentiated into retinal organoids based on an 
established protocol52. At day 90, total RNA was harvested from suspension retinal 
organoids for both the diseased and corrected cell lines. Total RNA was also collected 
from adherent wild-type iPSC as a control for determining the mean fold change in 
gene expression using the Livak method. There was no significant difference in 
expression of neural retina markers (Figure 17).  
Embryoid bodies were formed in microspace plates to control for the size and 
plating density at day 28. All six patient-derived cell lines produced embryoid bodies 
that subsequently produced the signature horseshoe morphology that is used to 
identify neural retina in adherent culture (Figure 18). Retinal organoids were 
measured in culture from day 41 to day 194 and there was no significant difference 
between the growth of the diseased and corrected organoids, which the exception of 
Day 111 and Day 194 (Figure 19).  
In suspension culture, a sub-population of the organoids developed an outer 
lamina that implied the presence of an outer retinal layer. Organoids were collected 
at various time points between day 70 to day 194 for sectioning and 
immunofluorescence. Retinal organoids were screened for mature morphology and 
were shown to express rhodopsin in few of the organoids at what appears to be distal 
to the outer nuclear layer (Figure 20).  
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Figure 17. Gene expression in retinal organoids. 
Diseased and corrected cells express similar levels of PRPF8 and retina specific 
genes (PAX6, RLBP1, CRX, VSX2, and CRB1).  
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Induced pluripotent stem cells are grown to 75-100% confluence prior to single 
cell passaging (A-B), Embryoid bodies are formed in microwells for 7 days (C-D), 
Embryoids are seeded at a density of 20 bodies per cm2 to allow for the formation 
of horseshoe morphology (E-F) Retinal organoids are matured for 70 to 200 days 
(G-H). Scale bar equals 100 µm. 
Figure 18. Differentiation process for retinal organoids. 
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Figure 19. Growth curve for patient-derived retinal organoids. 
 Retinal organoids were kept in culture for 194 days and imaged regularly to 
determine growth rate. Each time point consists of 10-20 organoids.  
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Figure 20. Retinal organoids form rhodopsin-expressing outer segments. 
 Wild-type human embryonic stem cells are able to produce mature organoids 
with rhodopsin expression distal to the photoreceptor inner segment as shown 
by localization of CRB1 (A). Diseased patient-derived cell lines are able to 
produce Müller glial cells and rhodopsin expression distal to the outer nuclear 
layer (B).  Scale bar equals 100 µm. 
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4. Discussion  
In this study, we show that patient-derived pluripotent cells are able to form 
retinal organoids that mimic the in vivo development of the retina.  
The first report of in vitro development of an optic-cup structure was reported 
in 2011122. Similar to the development of other organoids, the most incredible feature 
is the ability of cells to self-organize in a way that mimics in vivo tissues. Since the 
initial report of retinal organoid development, there have been several publications 
regarding specific methods for differentiation51–53. Most protocols involve some 
combination of adherent and suspension culture, making these methods particularly 
labor intensive and highly variable. As shown in Figure 18, stem cells begin in 
adherent culture, proceed to embryoid body suspension culture, return to adherent 
culture for the identification of neural retina, and finally allowed to grow in 
suspension for weeks to months at a time. 
While we have not quantified this result, we observe that the embryoid bodies 
tend to develop a large number of neural rosettes and amorphous structures rather 
than the desirable “horseshoe” morphology. This tendency made it impossible to 
produce organoids with the same efficiency as a purified cell type such as retinal 
pigmented epithelial cells. Established protocols call for a specific seeding density of 
embryoid bodies per cm2 at day 7 of the procedure (Figure 18E-F). We originally used 
non-adherent tissue culture plates to produce embryoid bodies, but this resulted in 
varying numbers and sizes of the embryoid bodies. By using the microwells, we were 
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able to control the size of the embryoid bodies and seed a more precise number of 
bodies per cm2 to minimize the variation between cell lines and differentiation 
batches.  
In addition to RNA and protein level expression of retina-specific genes, the 
organoids also adhered to the growth rate that was demonstrated in wild-type cells52. 
In this analysis, we only considered the size of organoids with laminated exteriors 
and excluded amorphous, opaque organoids that are removed from culture in most 
retinal organoid protocols. Given the results of cell cycle arrest in the functional 
analysis of RPE in chapter III, we hypothesized that the diseased retinal organoids 
may grow at a slower rate. Although the corrected organoids were significantly larger 
at day 111 and day 194, these results were limited to only two of the time points 
measured (Figure 19).  
In previous iPSC disease models of retinitis pigmentosa, retinal organoids were 
screened for morphological differences related to the disease. In the case of splicing 
factor retinitis pigmentosa, morphological affects remain largely unknown. Our 
results demonstrate potential problems with cell cycle progression, which may be 
related to ciliogenesis. Retinitis pigmentosa caused by a number of mutations have 
been identified as ciliopathies in both photoreceptors and RPE. The data presented 
here suggest that retinal organoids produced from PRPF8 mutants should be 
examined for indications of ciliopathy. Future studies may help identify 
morphological differences that were not immediately detectable in the retinal 
organoids produced during this study.   
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B. Autosomal recessive retinitis pigmentosa: CRB1 
1. Introduction  
The crumbs homologue 1 (CRB1) gene encodes for an apical transmembrane 
protein, which functions in cell-cell interactions and establishment of cell polarity. The 
human protein was first discovered as a homologue to the CRB protein in Drosophila 
melanogaster and was determined to be the causative gene involved in RP12, a severe 
form of autosomal recessive retinitis pigmentosa123. CRB1 is critical in the 
morphogenesis of photoreceptors and is located on the inner segment of mammalian 
photoreceptors124. Genetic screening of autosomal recessive retinitis pigmentosa 
patients has identified novel missense mutations shown to cause RP12 and Leber 
congenital amaurosis, the earliest onset and most severe inherited retinal 
dystrophy125,126. 
Due to the conservation across species, investigation of RP12 in non-human 
models may provide relevant pathological information (Figure 21). A mouse model 
of RP12, referred to as retinal degeneration 8 (rd8), was established by introducing a 
one base pair deletion in CRB1 that causes a frame shift mutation and premature stop 
codon127.  Gene transfer of CRB2 targeted to photoreceptors and Müller glial cells 
rescued the structure of photoreceptors in the rd8 mouse, which provided the first 
pre-clinical evidence of gene therapy in RP12128. CRB1, CRB2, and CRB3 are part of a 
crumbs complex in the retina that connects photoreceptors and glial cells. Although 
there has been success in using CRB2 to treat CRB1 deficient mice, the crumbs 
complex is drastically different in mice versus humans. Most notably, CRB1 is a 
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transmembrane protein in both photoreceptors and glial cells in humans, whereas 
CRB2 is a membrane associated protein in both cell types in mice. Due to these 
differences in cellular anatomy, it is critical to model RP12 in human retinal cells to 
accurately recapitulate normal human development and disease.  
Stem cell-derived retinal organoids provide a tool for studying the localization 
and function of CRB1 in vitro. Differentiation methods demonstrate the development 
of functioning photoreceptor outer segments in culture49–54. Previous studies have not 
tested for the expression of CRB1 in the inner segment of the resulting retinal 
organoids. We have access to a RP12 patient with two novel missense mutations, one 
on each allele: Cys698Arg and Leu878Pro (unpublished). Missense mutations 
including W675C, C891G, and N894S have all been shown to cause RP12123,129,130. Prior 
to gene editing of the patient stem cells, we established the ability to study the crumbs 
complex in stem cell-derived retinal organoids from wild-type cells.  
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Multiple sequence alignment for CRB1 demonstrates the conservation of CRB1 in 
mammals with less consensus among non-mammals. Amino acids at positions 
675, 891, and 894 are known causative mutations, whereas mutations at positions 
698 and 878 are novel.  
Figure 21. RP12 causative mutations in CRB1. 
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2. Materials and Methods 
Differentiation of pluripotent stem cells to retinal organoids  
 H9 human embryonic stem cells were seeded onto Matrigel-coated 6 
well plates (Corning) and cultured for 3 to 7 days before passage by Versene for 
embryoid body formation. Neural induction and retinal differentiation were 
performed as described in Zhong et al. 2014 52. Media formulations included neural 
induction media (NIM) and retinal differentiation media 1, 2, and 3. NIM consisted of 
1:1 DMEM:F12, 1 X N2, 1 X NEAA, and 2 µg/mL heparin (STEMCELL Technologies). 
RDM1 was used from day 16 to day 28 and consisted of 3:1 DMEM:F12 1 X B27 
without Vitamin A, 1 X NEAA. RDM2 consisted of 3:1 DMEM:F12, 1X B27, 1X NEAA, 
and RDM3 consisted of 3:1 DMEM:F12, 1 X B27, 1 X NEAA, 10% fetal bovine serum 
(Atlanta Biologicals), 100 µM taurine, and 2 µM GlutaMAX (Fisher Scientific).  
Cryosectioning  
  Retinal organoids (ROs) were removed from suspension culture at day 120. 
Individual ROs were placed in single wells of a 24 well plate and fixed in 4% 
paraformaldehyde (PFA) in 0.1M sodium cacodylate buffer, pH 7.4, for 20 minutes at 
room temperature on an orbital shaker in the dark. Samples were imaged and stored 
for up to 1 month in 0.1% PFA. Fixed samples were rinsed three times for 5 min in 
cold PBS and cryoprotected in a sucrose gradient: 10%, 20%, and 30% sucrose in PBS 
for 1 hr each followed by 40% sucrose in PBS overnight on an orbital shaker. Samples 
were placed in disposable plastic molds, embedded in Optimal Cutting Temperature 
Compound (OCT, Fisher Scientific, Hampton, NH, http://www.fishersci.com/), and 
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frozen on dry ice to store at -80 °C. Frozen samples were cut into 10-20 µm sections on 
a Leica Cryostat CM1850 (Leica, www.leica-microsystems.com) at -20 °C and adhered 
to SuperFrost Plus Microscope Slides (Fisher Scientific). 
Immunofluorescence 
  
  Retinal organoid samples were washed twice with cold PBS then blocked with 
5% bovine serum albumin (BSA) (Millipore Sigma) with 0.2% Triton X-100 to 
permeabilize the cell membrane. After blocking, ROs were incubated overnight at 4 
°C with primary antibody. Cells were washed three times with cold PBS, incubated 
with the corresponding secondary antibody conjugated to AlexaFlour (1:300) 
(Invitrogen) or Cy2, 3, or 5 (1:200)(Jackson-Immuno) for 1 hr at 4 °C, incubated with 
Hoechst (2 µg/mL)(Invitrogen) for 5 min at room temperature, washed three times 
with PBS, mounted with 80 µL Prolong Gold Mountant (Invitrogen) and coverslip, 
and imaged on Olympus IX70 Inverted Compound microscope, Olympus Fluoview 
1000 Spectral Confocal microscope (Olympus, www.olympusamerica.com), or Leica 
SP8 Resonant Confocal microscope (Leica, www.leica-microsystems.com).  
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3. Results 
Characterization of retinal organoids  
Retinal organoids were differentiated from human embryonic stem cells 
according to published protocol52. Localization of CRB1 in wild-type hESC-derived 
retinal organoids was observed using immunofluorescence (Figure 22). Figure 23 
shows in all three organoids that were examined, CRB1 was properly localized on 
what is presumably the inner segment of a photoreceptor precursor. The organoids 
expressed varying amounts of rhodopsin, which is expected based on previous 
reports52. CRB1 co-localized with the Müller glial cells as indicated by vimentin, 
which is expected as both photoreceptors and Müller glial cells express CRB1.  
Retinal organoids were examined for gene expression of CRB1 at day 90 of 
development. In this work, the diseased and corrected cells correspond to the patient-
derived cells used for studying autosomal dominant RP13. In comparison to adherent, 
wild-type iPSCs that were grown in the same media for 90 days, the suspension retinal 
organoids highly expressed CRB1. Although these cell lines do not correspond to the 
gene-corrected cells targeting CRB1, this demonstrates that CRISPR-edited stem cells 
can produce mature retinal organoids with similar expression of CRB1 (Figure 24).  
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Figure 23. Müller glial cells within hESC-derived retinal organoids.  
 
 
 
 
 
 
 
  
Figure 22. Photoreceptors within hESC-derived retinal organoids.  
CRB1 is properly localized proximal to the rhodopsin expressing outer segment. 
N=3. Scale bars, 100 µm. 
 
CRB1 is co-localized with vimentin expressing glial cells. N=3. Scale bars equals 
100 µm. 
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Figure 24. Expression of CRB1 RNA.  
 Suspension culture of patient-derived retinal organoids express significantly 
higher levels of CRB1 than adherent cultures. 
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4. Discussion  
In these experiments, we show that CRB1 is expressed at the transcript and 
protein level in retinal organoids and is correctly localized to the photoreceptor inner 
segment in suspension culture. This is the first demonstration that CRB1 co-localizes 
to vimentin in retinal organoids. This implies that CRB1 may be expressed in both the 
photoreceptor inner segment as well as Müller glial cells. 
In disease modeling, the correction of a mutation in a patient-derived line and 
subsequent functional rescue can demonstrate the necessity of a mutation. In contrast, 
the introduction of a mutation into wild-type stem cells and subsequent pathology 
can demonstrate the sufficiency of a mutation (Figure 1). This distinction is especially 
useful in the case of the current patient that has two different recessive mutations. To 
address the issue of sufficiency, CRISPR-induced mutations have been introduced 
into wild-type alleles at amino acid positions 698 or 878. Although there has been 
significant progress in gene-correction using CRISPR/Cas9, it is only just recently that 
detailed protocols have been provided for obtaining gene-corrected cells115. The gene-
corrected clones produced thus far have resulted in truncated versions of the CRB1 
protein rather than the introduction of a specific point mutation.  
Although the CRISPR-edited lines for the CRB1 RP12 patient cells have not 
been useful thus far, the gene-corrected lines from the PRPF8 RP13 patient provide an 
opportunity to observe the genetic expression of CRB1 in unedited and CRISPR-
edited cell lines. As expected, the suspension retinal organoids expressed high levels 
of CRB1 transcript relative to the wild-type adherent neural retina. Wild-type iPSCs 
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were left in adherent culture to ensure ample amounts of RNA to include in all PCR 
experiments as a control. As the yield of the production of retinal organoids is 
improved, it may be possible to collect sufficient amounts of RNA from suspension 
culture to serve as a wild-type control.  
With regards to protein expression and localization of CRB1, we hypothesized 
that the mutated CRB1 would result in abnormal CRB1 localization or complete 
absence in the Müller glia and photoreceptors. This was based on speculation from 
three current mouse models Crb1-/-, Crb1C294W/-, Crb1rd8 that demonstrated the loss of 
adherens junctions at the outer limiting membrane131. Initial immunofluorescence 
analysis showed there was not a complete loss of CRB1 expression at the inner 
segment of the photoreceptors. However, the truncated version of the protein may 
not mimic the patient-specific mutation. Furthermore, the crumbs complex in mice is 
vastly different than that found in humans, indicating that results from the mouse 
model may not be an accurate representation of the human retina.  
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C. Conclusions 
Our findings demonstrate that PRPF8 patient-derived cells can produce retinal 
organoids. In addition, we show that retinal organoids express CRB1 protein. Earlier 
work has shown the ability to differentiate stem cells into neural retina organoids, and 
it is vital to show the reproducibility of the differentiation process across diseased and 
wild-type stem cells. While morphological differences were not identified or 
quantified for the PRPF8 diseased retinal organoids, the presence of CRB1 and the 
functional role of CRB1 in cell-to-cell junctions provide an avenue for future 
morphological studies in disease modeling of autosomal recessive retinitis 
pigmentosa. 
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VI. Appendix 
Table 1. Primary Antibodies 
Target Protein Clonality/ 
Immunoglobulin 
Host Source/ 
Catalog Number 
RPE65  monoclonal/IgG1 mouse Millipore/MAB5428 
PMEL monoclonal mouse Dako/ M0634 
PRPF8 polyclonal rabbit abcam/ ab87433, ab79237 
ZO-1 polyclonal rabbit abcam/ ab59720 
BEST1 monoclonal/ IgG1 mouse abcam/ ab2182 
BRN3a polyclonal rabbit Millipore/ AB5945 
CRB1 polyclonal/ IgG rabbit abcam/ ab156282 
RCVRN monoclonal mouse abcam/ ab31928 
RHO monoclonal/ IgG1 mouse Millipore/ MAB5316 
VIM polyclonal chicken Millipore/ AB5733 
GAPDH monoclonal/ IgG1 mouse ThermoFisher/ MA5-15738 
 
Table 2. Secondary Antibodies 
Target  Fluorophore/  
Immunoglobulin 
Host Source/ 
Catalog Number 
anti-chicken Cy3 / IgY, IgG (H+L) donkey Jackson Immuno/703-165-155 
anti-mouse Cy5 / IgG (H+L) donkey Jackson Immuno/715-175-150 
anti-rabbit Cy2 / IgG (H+L) donkey Jackson Immuno/711-225-152 
anti-mouse Cy3 donkey Jackson Immuno/715-165-150 
anti-rabbit Cy3 donkey Jackson Immuno/711-165-752 
anti-mouse 800CW donkey LI-COR/ 925-32212 
anti-rabbit 680RD donkey LI-COR/ 925-68073  
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Script 1. Differential Expression Analysis of RNA-Seq raw count data 
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